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ABSTRACT 
 
Spinal muscular atrophy (SMA) is a genetic disease which is characterized by 
muscle weakness and atrophy. The disease arises from mutations in the survival 
motor neuron 1 (SMN1) gene causing degeneration of spinal cord motor neurons. 
No effective treatment is currently available for SMA however it may be possible to 
treat the disease using gene therapy. The aim of this project is to develop potential 
therapies for SMA by investigating different viral and non-viral gene therapy vectors 
and assessing the effect of potential disease modifying genes. The data collected 
are described under four chapters as follows: 
1: The aim here was to develop a novel approach based on polymer nanoparticles 
(polymersomes) for gene delivery. Encapsulation of DNA by polymersomes was 
optimised and polymersomes were used to restore SMN levels into a fibroblast cell 
line isolated from a child with severe SMA. 2: The ability of adeno-associated virus 
serotype 5 (AAV5) vectors expressing GFP to transduce the central nervous system 
(CNS) following intravenous injection was tested in neonatal wild-type mice. Overall 
transduction efficiency of AAV5-GFP in the brain was low and very few lumbar spinal 
cord neurons were found to be transduced, suggesting that AAV5 is not an 
appropriate vector to treat diseases such as SMA. 3: AAV6 was used to overexpress 
hnRNP R in an in vivo model of SMA. hnRNP R is a candidate disease modifying 
gene for SMA due to its interaction with SMN and β-actin. However this strategy 
had only a very marginal effect on the phenotype and life-span of this SMA mouse 
model. 4: Finally AAV9 was used to silence phosphatase and tensin homolog (PTEN) 
in an in vivo model of SMA. PTEN is a negative regulator of growth which acts on 
the PI3K/Akt pathway. AAV9-mediated PTEN silencing resulted in a significant 
increase in the lifespan of a SMA mouse model coupled with an improved 
phenotype. 
In conclusion this work highlights two major findings: i) polymersomes can be used 
to deliver SMN plasmid DNA to restore SMN mRNA and protein levels in an in vitro 
model of SMA; ii) AAV9-mediated silencing of PTEN can improve the phenotype and 
increase lifespan of a SMA mouse model. 
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1.1 Spinal Muscular Atrophy 
 
1.1.1 Clinical Features 
Spinal muscular atrophy (SMA) was estimated to have an incidence of 1 in 24,100 
live births and a prevalence of 1.2 per 10,000 live births in a study conducted in 
the north-east of England in 1978 (Pearn, 1978). More recent studies estimate the 
incidence of SMA to be as high as 1 in 6,000 with a carrier frequency of 1:38 
(Wilson & Ogino, 2008). There appears to be some discrepancy between the carrier 
frequency and the incidence of disease seen, with a lower incidence than the 
carrier frequency suggests. This may be due to severe prenatal forms of the 
disease that are not counted in incidence data (Prior et al., 2010). Classically this 
disease is characterised by weakness and atrophy in the proximal voluntary muscles 
which is known to be caused by loss of motor neurons in the anterior horn of the 
spinal cord. As the disease progresses more distal muscles become affected until 
muscles of the torso are also affected. SMA is a genetic disorder caused by 
mutation or deletion of the Survival motor neuron (SMN1) gene therefore diagnosis 
can be confirmed by genetic testing. The genetic cause of SMA will be discussed in 
more detail below. Diagnosis can be further assessed by electromyography and 
muscle biopsy. Electromyography measures the electrical activity of nerves in the 
muscle and can differentiate between SMA which is caused by nerve degeneration 
and muscle pathologies such as muscular dystrophy.  Muscle biopsy is rarely used 
now due to the invasive nature of the procedure and the effectiveness of genetic 
testing.  
The rate of disease progression and severity of disease differs between patients 
therefore SMA is divided into three main types; type I, II and III. Type I is the most 
severe and was the first to be described.  Patients are usually asymptomatic at 
birth but start to display symptoms from around 2 months. These children present 
with weak, thin, hypertonic muscles and display poor breathing and feeding abilities 
(Wang et al., 2007; Lunn & Wang, 2008; Markowitz et al., 2012). SMA patients are 
usually divided into type I, II or III based on what major motor milestone they 
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achieve (Wang et al., 2007) (table 1.1). For example type I patients are never able 
to sit, whereas intermediate type II patients are able to sit but cannot walk. Patients 
with the less severe type III SMA are able to walk however as they age and the 
disease worsens this ability is lost. There are also two further categories of SMA, 
type 0 and type IV. Type 0 denotes those patients that are symptomatic at birth 
whereas type IV is a rare form with onset in adulthood and a normal life 
expectancy. Type I SMA is the most common form of the disease and patients have 
a life expectancy of 2 years, with the cause of death usually being respiratory 
failure. Type II SMA has an onset of between 6 and 18 months, with a life 
expectancy of up to teenage years. Type III SMA has an onset from 18 months and 
these patients usually live to adulthood. However these classifications are not exact 
with variations seen in the age of onset and motor ability which reflects a spectrum 
of disease severity.   
Table 1.1 Classification of spinal muscular atrophy 
 
Disease Type Onset Major Function Achieved Life expectancy 
0 Prenatal Need respirator from birth < 6 months 
I < 6 months Never sit < 2 years 
II 6 – 18 months Sits with assistance > 2 years 
III > 18 months Stand and walk Adulthood 
IV 10 – 30 years Walks normally Normal 
(Wang et al., 2007; Markowitz et al., 2012) 
 
1.1.2 Motor Neuron Dysfunction in SMA 
The classical presentation of muscle weakness and atrophy in SMA is caused by 
degeneration of spinal cord motor neurons. Electrophysiological testing has been 
used to estimate the number of motor units innervating a muscle group in SMA 
patients. This revealed a decrease in muscle innervation over time in type I, II and 
III SMA (Swoboda et al., 2005). Animal models of SMA show axon degeneration and 
neuromuscular junction (NMJ) defects caused by decreased SMN protein in 
zebrafish, drosophila and mice (Chan et al., 2003; McWhorter et al., 2003; Rossoll et 
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al., 2003; Jablonka et al., 2004; Winkler et al., 2005; Boon et al., 2009; Kong et al., 
2009). Motor neurons in spinal cords of SMA patients display abnormal migration 
towards the ventral root and a lack of differentiation (Simic et al., 2008). 
Furthermore lack of differentiation and poor synapse formation causes abnormal 
migration of motor neurons towards the ventral roots of spinal cords before later 
succumbing to necrosis. Impaired growth of axons is caused by a lack of SMN 
protein in the growth cone of motor neurons. This leads to abnormalities at the 
synapse and neuromuscular junction.   Defects in axonal growth are caused by 
impaired trafficking of molecules such as β-actin which causes neurons to become 
chromatolytic and eventually die (Rossoll et al., 2003). Neuromuscular junctions also 
display defects in the structure of pre- and post-synaptic apparatus including 
changes in receptor clustering and accumulation of vesicles (Martinez-Hernandez et 
al., 2013). A mild model of SMA displays altered NMJ morphologies and decreased 
neurotransmitter release (Ruiz & Tabares, 2013).  
Defects in NMJ and muscles appear to only affect some muscles; NMJ defects have 
been reported in the diaphragm but not the soleus muscle (Voigt et al., 2010; Lee 
et al., 2011b). Selective denervation of muscles has been reported  throughout the 
body with various muscle fibre types being affected (Ling et al., 2012). Loss of 
innervation of muscles is thought to be due to defects in synaptic maintenance or 
maturation. Interestingly selective expression of SMN protein in neurons can restore 
motor neuron synapses and NMJ defects however this can only increase survival by 
up to three weeks, suggesting that SMN replacement is required in other tissues to 
be an effective treatment (Martinez et al., 2012). Furthermore zebrafish with low 
levels of SMN have shorter axons with fewer branches and significant motor defects 
(Hao et al., 2013). Defects in axonal transport of synapse proteins have been 
reported in a mouse model of SMA which suggests a reason for defects in 
synapses and NMJs of motor neurons (Dale et al., 2011). Defects in the NMJ have 
been linked with muscle dysfunction which may also be independent from the motor 
neuron pathology of SMA. This reveals the possibility of other tissues also being 
affected by SMN deficiency. 
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Interestingly there is evidence that sensory nerves are also affected in SMA. 
Drosophila with mutations in the SMN gene have defects in proprioceptive nerves 
and interneurons (Imlach et al., 2012). Meanwhile SMN-deficient mice display a 
reduction in the strength of connections between primary afferent neurons and 
motor neurons (Mentis et al., 2011). Patients with type I SMA have also been shown 
to have abnormalities in peripheral nerves (Yonekawa et al., 2013).  
 
1.1.3 Non-neuronal Pathology 
SMN is a ubiquitously expressed protein (Lefebvre et al., 1995) therefore the 
reduced levels of SMN protein seen in SMA is likely to affect other cell types as 
well as motor neurons. It has recently become apparent that many other tissues are 
also affected in SMA (Hamilton & Gillingwater, 2013). This is partially due to 
prolonging the lifespan of SMA patients revealing symptoms that do not usually 
become apparent such as digital necrosis. Digital necrosis has been reported in 
type I SMA patients (Heier et al., 2010; Rudnik-Schoneborn et al., 2010) which is 
thought to be due to defects in the vasculature. This is supported by the presence 
of cardiac defects which have been reported in SMA patients and in animal models 
(Rudnik-Schoneborn et al., 2008; Heier et al., 2010; Shababi et al., 2010). In the 
most severe cases of SMA patients various congenital cardiac problems such as 
atrial and ventricular septal defects have been reported (Rudnik-Schoneborn et al., 
2008). Assessment of the cardiac function of SMA mice revealed that these mice 
suffer from severe bradyarrhythmia from as early as 2 days of age which worsened 
as the disease developed (Heier et al., 2010). The hearts of these mice appeared 
smaller and lacked a defined shape however the ratio of heart weight to body 
weight was comparable to that of unaffected litter-mates.  Histological analysis has 
shown that hearts of SMA mice have thinner inter-ventricular septums (Shababi et 
al., 2010).  Interestingly muscle capillaries are also defective in a mouse model of 
SMA, with defects becoming apparent as mice age (Somers et al., 2012). 
Interestingly ECG studies on milder type II and III patients reveal that these patients 
do not have any cardiac dysfunction (Palladino et al., 2011).  
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Other organs such as the lung, liver, pancreas and intestine also display 
abnormalities in SMA patients or animal models. In a mouse model of severe SMA 
analysis of pancreatic cells revealed increased glucagon-producing α cells and fewer 
insulin-producing β cells (Bowerman et al., 2012). This causes these mice to display 
fasting hyperglycaemia, hyperglucagonemia and glucose resistance. Children with 
type I SMA also have abnormalities in pancreatic islets with some patients displaying 
glucose intolerance (Bowerman et al., 2012). The liver also appears to be affected 
in SMA; a decrease in hepatic IGF-binding protein acid labile subunit (Igfals) and 
resulting reduced levels of circulating IGF1 has been reported in SMA mice (Hua et 
al., 2007). This corroborates with the finding that the liver specific deletion of 
murine SMN exon 7 causes severe impairment of liver development (Vitte et al., 
2004). Bone abnormalities have been reported in vertebrae of a severe mouse 
model of SMA (Shanmugarajan et al., 2007; Shanmugarajan et al., 2009).   
 
1.1.4 Genetics of SMA 
The genetic cause of SMA was determined in 1995 as the mutation of a gene on 
chromosome 5q13 which was termed the survival motor neuron (SMN) gene 
(Lefebvre et al., 1995). The area of the chromosome where this gene is located is 
unstable and contains duplications. There are two copies of the SMN gene, a 
telomeric copy (SMN1) and a centromeric copy (SMN2), these two genes differ by 5 
single nucleotide changes however it is the difference in exon 7 which is most 
important. This single nucleotide change in exon 7 of SMN2 affects how it is 
spliced. The C-T transition at codon 280 does not alter the sequence of amino 
acids but does result in the loss of an exon splice enhancer, and the creation of a 
novel splicing silencer. This causes exclusion of exon 7 and the production of a 
truncated protein which is unstable and quickly degraded (Lorson et al., 1999; 
Cartegni & Krainer, 2002). However exon 7 of SMN 2 is not always skipped, 
resulting in around 10% of full length protein being produced by SMN2. Since SMN1 
is either deleted or mutated in patients only have the small amount of SMN protein 
produced from SMN2. The number of copies of the SMN2 gene varies throughout 
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the population. Increased SMN2 copy number reduces the severity of SMA by 
providing greater amounts of full-length SMN. Type II SMA patients usually have 3 or 
more copies of SMN2 which produce around 14% of the normal amount of SMN 
protein whereas patients with the milder type III form can have up to 8 copies of 
the SMN2 gene (Simic, 2008). The correlation between SMN2 copy number and 
disease severity is not perfect however; patients with three copies of SMN2 have 
been seen to have all three main disease types. This suggests that there may be 
disease modifying genes acting in some SMA patients. Interestingly a mutation in 
SMN2 has been reported which increases the inclusion of exon 7 resulting in a less 
severe phenotype. There appears to be an inverse correlation between SMN1 and 
SMN2 levels in the general population (Ogino et al., 2003). People with more copies 
of SMN1 have fewer copies of SMN2. De novo mutations in SMN1 have been 
reported in patients with SMA resulting in conversion to SMN2 (Prior et al., 2010) 
and SMN2 can also be converted into SMN1 through mutations.    
 
 
 
 
 
 
Figure 1.1 Variable splicing of SMN1 and SMN2. A single nucleotide mutation in exon 
7 of the SMN2 gene causes exon 7 to be skipped resulting in the production of a 
truncated protein. However a small amount of full length protein is still produced by the 
SMN2 gene. (Lorson et al., 1999; Cartegni & Krainer, 2002) 
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1.1.5 Role of SMN 
The SMN protein is present in both the cytoplasm and the nucleus of all cells. In 
the nucleus it forms a complex with many other molecules and associates in 
structures known as gems (Liu & Dreyfuss, 1996). The core of the complex consists 
of SMN, Gemin7 and Gemin8, with other Gemins and Unrip binding to these three 
proteins (Otter et al., 2007). The SMN complex is involved in initiating pre-mRNA 
splicing by causing Sm core proteins to bind small nuclear RNAs and assemble 
specific uridine rich small nucleotide ribonuclear proteins (snRNPs). These snRNPs 
are then translocated to the nucleus to perform pre-mRNA splicing as components 
of the spliceosome complex. The SMN protein is therefore indirectly involved in 
mRNA processing through the assembly of snRNPs and can also bind various other 
proteins involved in RNA processing such as RNA-helicase A, fibrillin and 
ribonucleoproteins. Furthermore SMN can also directly bind mRNA to act as a 
translational regulator (Sanchez et al., 2013).  
 
 
Figure 1.2 The Role of the SMN complex. The SMN complex initiates binding of Sm 
core proteins and small nuclear RNA to assemble snRNPs which are then incorporated 
in the spliceosome complex to perform pre-mRNA splicing in the nucleus. 
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1.1.5.1 Neuron Specific Role of SMN 
Since motor neurons are most affected by SMN disruption in SMA it stands to 
reason that the SMN protein may play a specific role in motor neurons. SMN is 
widely expressed in the central nervous system (CNS), particularly in lower motor 
neurons of the spinal cord (Battaglia et al., 1997). A differentially spliced form of 
SMN was identified which was termed axonal-SMN and was found to be selectively 
expressed in motor neurons and was mainly localized in axons (Setola et al., 2007). 
The SMN protein appears to play a variety of roles within the motor neuron 
including neurite outgrowth as it is found in the growth cone and axon branching 
points. The SMN protein is trafficked along axons of motor neurons in granules 
along with Gemin 2 and Gemin 3. SMN reduction is associated with a decrease in 
β-actin protein and mRNA levels in motor neuron axons. SMN regulates β-actin 
levels through interaction with hnRNP R which associates with β-actin mRNA and 
with profillin II. Profillin II inhibits β-actin polymerisation however upon binding with 
SMN actin polymerisation occurs. Neurite growth is reduced in differentiated PC12 
cells following SMN knockdown (Rossoll et al., 2003). Similarly reduced SMN levels in 
zebrafish cause axon growth defects, increased branching and defective path-finding 
(McWhorter et al., 2003). Furthermore motor neurons cultured from a severe SMA 
mouse model display truncated axons (Rossoll et al., 2003). The effect of SMN on 
β-actin suggests a mechanism for the axon outgrowth defects seen in SMA models. 
However SMN deficiency also causes defects in motor neuron synapses and 
neuromuscular junctions. Disruption of presynaptic organisation and synaptic 
maturation has been reported in motor neuron terminals of SMA mice (Torres-Benito 
et al., 2011). 
 
1.1.6 Other Molecules Involved in SMA 
As mentioned above SMN interacts with many other proteins both in the nucleus 
and in motor neuron axons and growth cones. Furthermore a variety of proteins 
have been shown to modify SMA pathology. Actin appears to play an important role 
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in the motor neuron pathology of SMA highlighted by the reduction of actin protein 
and mRNA levels in growth cones of SMN-deficient motor neurons (Rossoll et al., 
2003; Ning et al., 2010). Profilin II and hnRNP R have been shown to interact with 
both SMN and β-actin. Plastin and profilin have also been implicated in actin 
dysregulation in SMA, profilin II is increased in SMA mice whilst plastin 3 is down-
regulated however restoration of both these proteins to the correct level does not 
rescue the SMA phenotype (Bowerman et al., 2009). Profilins are known to control 
β-actin dynamics and SMN strongly binds to profilin II which is predominantly 
expressed in motor neurons (Giesemann et al., 1999). Furthermore SMN deficiency 
affects laminin mediated local translation of β-actin in the growth cone of motor 
neurons (Rathod et al., 2012). As well as binding to other proteins SMN also 
associates with mRNA such as β-actin mRNA (Todd et al., 2010). 
The RNA binding protein hnRNP R co-localizes with SMN in purified motor neurons 
and also associates with β-actin mRNA (Rossoll et al., 2003). Interestingly hnRNP R 
knockdown causes axon defects similar to SMN deficiency and hnRNP R 
overexpression can increase axon length. SMN has also been shown to associate 
with various other molecules in motor neurons involved in RNA binding including 
HuD and hnRNP Q (Chen et al., 2008; Akten et al., 2011; Fallini et al., 2011; Hubers 
et al., 2011). SMN is required for the recruitment of HuD and mRNA targets in 
neuronal RNA granules (Akten et al., 2011; Hubers et al., 2011). Furthermore SMN-
deficient motor neurons display reduced levels of HuD protein and mRNA in axons 
(Fallini et al., 2011). SMN and HuD interact with candidate plasticity-related gene 15 
(cpg15) mRNA which is also reduced in SMN-deficient neurons (Akten et al., 2011). 
Interestingly overexpression of cpg15 in SMN deficient zebrafish can partially rescue 
their phenotype. Furthermore silencing of PTEN which acts on the PI3K/Akt pathway 
to regulate cell growth can rescue the shortened axons of SMN-deficient cultured 
motor neurons (Ning et al., 2010). Intramuscular injection of AAV6 expressing siRNA 
against PTEN leads to increased survival of spinal cord motor neurons. This 
suggests the possibility of modulating SMA pathology through modification of the 
expression of other molecules.  
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1.1.7 Models of SMA 
 
1.1.7.1 In Vitro Models of SMA 
The availability of SMA models has been important in elucidating the complex 
functions of the SMN protein and the pathology of SMA. In vitro models are 
especially useful for understanding molecular pathways involved in SMA and early 
testing of potential therapies. In vivo models are useful for understanding the full 
phenotype of SMA as well as in depth testing of potential therapeutics (table 1.2). 
RNAi can be used to create in vitro models by silencing SMN by delivering siRNA 
against SMN to cells (Trulzsch et al., 2004; Trulzsch et al., 2007). An SMA cell line 
has also been created from a type I SMA patient which can reduce the variability 
within the model. Fibroblasts from SMA patients display low SMN expression and 
almost complete absence of SMN gems (Coovert et al., 1997). Differentiated P19 
cells have also been used to model the effect of SMN depletion in motor neurons, 
as have primary motor neuron cultures (Trulzsch et al., 2007).   
 
1.1.7.2 Animal Models of SMA 
SMA has been modelled in various animal species however modelling is complicated 
by the fact that only humans and chimpanzees carry multiple copies of the SMN 
gene. Complete knockout of SMN in mice is embryonically lethal therefore various 
strategies have been developed to produce a partial expression of SMN (Schrank et 
al., 1997). Cre-loxP can be used to drive tissue specific SMN knockdown and has 
been used to knockdown SMN in either muscle or in neurons (Frugier et al., 2000; 
Cifuentes-Diaz et al., 2001). Interestingly targeted deletion in either muscle or 
neurons both cause motor defects. Specific knockdown of SMN in motor neurons 
caused tremors and severely reduced life expectancy (Frugier et al., 2000). These 
mice also display denervation of skeletal muscle and motor neuron defects in the 
spinal cord. Meanwhile muscle specific silencing of SMN leads to severe muscle 
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defects by 4 weeks causing paralysis and necrosis of muscle cells (Cifuentes-Diaz et 
al., 2001). Interestingly these mice have morphologically normal motor neurons. This 
suggests that SMN may also play an important role in skeletal muscle.  
Another way of overcoming the lethality of SMN knockout in mice is to introduce a 
human SMN gene. A mouse model was created with a complete knockout of the 
mouse Smn gene but with the introduction of the human SMN2 gene in order to 
replicate the situation found in humans with SMA. These mice have a severe SMA 
phenotype with reduced numbers of motor neurons and survival of around 5 days. 
Interestingly the SMN2 copy number can determine the severity of this mouse 
model, as it does in humans (Hsieh-Li et al., 2000; Monani et al., 2000). Neuron-
specific expression of SMN is also able to reduce the severity of the SMA 
phenotype in this mouse model. Furthermore mice have also been generated that 
carry the human SMN gene without exon 7 (SMNΔ7). These mice were bred with 
mice that carried the human SMN2 gene and mouse Smn knockout. This resulted in 
mice with both the SMN2 and SMNΔ7 genes but lacking any mouse Smn gene (Le 
et al., 2005). These mice display a slightly less severe SMA-like phenotype and live 
for around 14 days.  
Zebrafish have also been used to model SMA by reducing SMN levels using 
antisense morpholinos (McWhorter et al., 2003). SMN-deficient zebrafish embryos 
died during development however developmental defects could still be investigated 
in the transparent embryos. Motor neuron axons from the spinal cord were 
truncated and displayed increased branching possibly due to a defect in axon 
growth. Use of siRNA mediated knockdown of SMN in zebrafish and xenopus which 
caused severe developmental defects (Winkler et al., 2005). Zebrafish carrying 
homozygous mutations in the SMN gene died during development and displayed 
abnormal neuromuscular junctions with reduced synaptic vesicle protein SV2.  
Drosophila mutants have been discovered with point mutations in Smn causing 
defects in motor neurons and locomotive ability (Rajendra et al., 2007). These flies 
had axon defects in motor neurons innervating flight muscles and also displayed 
actin disorganization. Another drosophila Smn mutant displayed abnormal motor 
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behaviour due to reduced synaptic transmission and disrupted glutamate receptor 
clustering (Chan et al., 2003).  
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Table 1.2 Animal models of SMA 
Animal Genotype Phenotype Lifespan Reference 
Mouse Smn-/-;SMN2+/+ Severe spinal cord 
and skeletal 
muscle defects 
4-5 days (Hsieh-Li et al., 
2000; Monani et 
al., 2000) 
Mouse Smn-/-; SMN2+/+; 
SMNΔ7+/+ 
Less severe than 
Smn-/- ; SMN2 
13 days (Le et al., 2005) 
Mouse Smn-/-; SMN2+/+; 
SMN(A111G)+/+ 
Moderate Over 1 year (Workman et al., 
2009) 
Mouse Neuron specific SMN 
exon 7 deletion 
Tremors and 
muscle 
denervation 
25 days (Frugier et al., 
2000) 
Mouse Muscle specific SMN  
exon 7 deletion 
Severe muscle 
defects and 
paralysis 
33 days (Cifuentes-Diaz et 
al., 2001) 
Zebrafish Smn knock-down Truncated axons Larval lethal (McWhorter et al., 
2003) 
Zebrafish siRNA-mediated 
SMN silencing 
Severe 
developmental 
complications 
Embryonic lethal (Winkler et al., 
2005) 
Zebrafish Mutations smnY262, 
smnL265, smnG264 
Neuromuscular 
junction 
abnormalities 
Embryonic lethal (Boon et al., 2009) 
Xenopus siRNA-mediated 
SMN silencing 
Severe 
developmental 
complications 
Embryonic lethal (Winkler et al., 
2005) 
     
Drosophila Hypomorphic Smn 
mutations 
Flightlessness, 
axon defects 
Depends on Smn 
expression levels 
(Rajendra et al., 
2007) 
Drosophila Smn73Ao zygotic 
mutant 
Progressive loss of 
mobility 
Adult, due to 
maternal smn 
(Chan et al., 2003) 
  
28 
 
1.1.8 Treatment Strategies for SMA 
There is currently no cure for SMA therefore treatment is centred around increasing 
the quality of life of patients through palliative care and relieving secondary 
symptoms. Many complications can arise due to the range of muscles that are 
affected and the various other organs affected by SMN deficiency. The main cause 
of mortality in type I and II SMA is pulmonary complications that arise from 
weakness of respiratory muscles (Oskoui & Kaufmann, 2008). Muscle weakness 
prevents efficient clearance of the lungs which leads to reduced gas exchange and 
alveolar collapse. Furthermore inefficient lung clearance can cause recurrent 
infection, however immunisation can prevent the risk of this. Chest physiotherapy 
used alongside postural drainage procedures and mechanically assisted cough 
devices can help improve lung clearance. Non-invasive ventilation systems can also 
be used to improve breathing and reduce the risk of asphyxiation, which is 
especially dangerous when patients are sleeping (Bach et al., 2000). Non-invasive 
ventilators are becoming smaller and more user friendly, with soft masks designed 
to fit young babies (Iannaccone, 2007). As well as reducing the risk of asphyxiation 
non-invasive ventilation can improve the growth of the lungs and prevent pectus 
excavatum and avoids the need for tracheostomy (Bach & Bianchi, 2003). 
Complications involving the gastrointestinal tract are common in SMA patients 
including constipation, delayed gastric emptying and gastroesophageal reflux. A 
combination of drugs can be used to control these symptoms including drugs to 
neutralize stomach acid, inhibit acid secretions and promote motility. Avoiding 
patients becoming malnourished is also an important consideration for the care of 
SMA patients. Type I patients have a higher energy expenditure due to breathing 
difficulties however fatigue and swallowing dysfunction may discourage feeding 
(Iannaccone, 2007). 
Weakness and immobility caused by SMA leads to problems with posture and spinal 
defects. Contractures and scoliosis develops gradually and incidence of 
kyphoscoliosis increases with age and loss of walking ability in type III patients 
(Oskoui & Kaufmann, 2008). Patients are encouraged to practice weight bearing, 
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standing and range of motion exercises and undergo physiotherapy to improve 
posture and reduce or delay onset of spinal defects. However the progression of 
kyphoscoliosis cannot be stopped and surgery is often required to maintain function 
and respiratory ability (Oskoui & Kaufmann, 2008). To aid development and 
increase independence young children can now use motorized wheelchairs to move 
around. This improves social interaction and enables children to better explore their 
environment (Jones et al., 2003). 
 
1.1.8.1 Drug Treatment Approaches 
Various compounds have been investigated for their ability to increase SMN2 
expression in clinical trials. One class of drug being investigated is histone 
deacetylase (HDAC) inhibitors. Histone acetylation plays an important role in gene 
expression and HDAC proteins associate with an SMN promoter, therefore it is 
thought that HDAC inhibitors could increase SMN2 expression levels. Phenylbutyrate, 
hydroxyurea and valproate are all drugs that have been approved for use in the 
treatment of other diseases and have been tested in patients and cell lines. 
Salbutamol and phenylbutyrate have been shown to increase SMN2 levels in patient 
fibroblasts. Treatment of type II and type III patients with salbutamol resulted in 
increased body mass, improved forced vital capacity and improved strength (Kinali 
et al., 2002). Daily treatment with salbutamol has also been tested in a pilot trial of 
23 children with type II SMA. Patients displayed significantly increased motor 
function over 12 months with no severe side effects (Pane et al., 2008). Salbutamol 
has been shown to cause an increase in SMN2 full length transcript levels in SMA 
type II and III patients following treatment for 6 months (Tiziano et al., 2010). 
Interestingly the increase in full length SMN2 was directly proportional to SMN2 
copy number. Phenylbutyrate has been shown to increase SMN2 levels in leukocytes 
of four patients with type II SMA as well as two patients with type III SMA (Brahe et 
al., 2005). However in a randomized double-blind trial of over 100 children there 
was no apparent effect on motor function or forced vital capacity (Mercuri et al., 
2007). 
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Treatment with Valproate generated an increase in SMN2 levels in the blood of 
patients (Brichta et al., 2006) as well as an increase in muscle strength in type III 
patients (Weihl et al., 2006). Furthermore analysis of the effects of Valproate 
treatment in different age groups revealed the drug caused the greatest increase in 
muscle strength in children, with a reduced effect seen in adolescents and no 
increase in the two adults tested (Tsai et al., 2007). Mice treated with Valproate 
displayed increased motor function, increased motor neuron survival and increased 
SMN protein levels. Following 12 months of valproic acid treatments type II and III 
SMA patients did not gain muscle strength however type II children did show 
improved activities of daily living and motor function (Darbar et al., 2011). A phase 
II study of valproic acid treatment in patients with type I, II and III SMA also showed 
some positive effects. Motor function improved in some type II patients however 
these were almost all below 5 years of age (Swoboda et al., 2009). Combinational 
treatment of valproic acid and L-carnitine has been tested in a phase II clinical trial 
of type II and III SMA patients. Type II patients showed no change in motor function 
after 6 months of treatments and many suffered from excessive weight gain. 
However children aged between 2 and 3 years showed improvement of motor 
function in the first 6 months when adjusted for weight (Swoboda et al., 2010). 
Type III patients also incurred excessive weight gain with no significant change in 
motor function (Kissel et al., 2011).  
Rizuole, a drug used to treat motor neuron disease, has also been trialled as a 
treatment for SMA (Russman et al., 2003). Survival in SMA mice was increased 
following Rizuole treatment however SMA patients that received Rizuole displayed no 
improvement in motor function. Thyrotropin-releasing hormone therapy has been 
shown to increase muscle strength and myometry in treated SMA children (Tzeng et 
al., 2000). Furthermore a single adolescent type III patient treated with Thyrotropin-
releasing hormone therapy displayed increased muscle strength and motor abilities 
with no adverse effects (Kato et al., 2009). Hydroxyurea was trialled in type II and III 
SMA patients but showed no improvement compared to placebo treated controls 
(Chen et al., 2010a).     
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Therefore there has been some success in finding compounds that can increase 
SMN2 levels and improve motor abilities in SMA patients however these molecules 
have mainly been tested on type II and III patients and have led to no significant 
improvement of lifespan or motor function. Whether these therapies can also 
successfully treat more severe type I patients is still to be elucidated.     
 
1.1.8.2 Gene Therapy Approaches 
Gene therapy has been used to successfully increase SMN expression in animal 
models of SMA. Self-complimentary adeno-associated viral vectors (scAAV) have 
been used to overexpress SMN resulting in an increase in lifespan and amelioration 
of the SMA phenotype. Three independent groups have used scAAV9 administered 
intravenously at postnatal day 1 to rescue the SMA phenotype and improve motor 
function in mice as well as increasing survival to over 340 days (Foust et al., 2010; 
Valori et al., 2010; Dominguez et al., 2011). Interestingly administration of scAAV8 
into cerebrospinal fluid (CSF) has also been shown to cause increased SMN 
expression in the spinal cord and increase median survival to 157 days (Passini et 
al., 2010). Furthermore intramuscular injection of scAAV9 to neonatal SMA mice can 
also cause widespread transduction of the spinal cord and also peripheral tissues. 
Astonishingly a single injection of AAV9 expressing SMN to the gastrocnemius 
muscle was able to increase the median lifespan of SMA mice to 163 days 
(Benkhelifa-Ziyyat et al., 2013). These recent studies demonstrate the potential of 
viral mediated gene therapy to rescue the SMA phenotype and point towards a 
promising method of treating SMA. AAV9 administration at postnatal day one can 
rescue the SMA phenotype in mice however administration at day 5 only partially 
ameliorated the phenotype and administration at day 10 had little effect (Foust et 
al., 2010). This demonstrates the narrow window available for therapeutic 
intervention in more severe forms of this disease.  
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1.1.8.3 Gene Repair 
One potential strategy for gene therapy to treat SMA is to target the SMN2 gene to 
drive the production of more full length protein. Antisense oligonucleotides can be 
used to block splicing in order to promote the inclusion of exon 7 in SMN2. Bi-
functional oligonucleotides have been designed to bind to exon 7 with a non-
complementary section known as the tail being used to mimic an exonic splice 
enhancer (Skordis et al., 2003). This leads to SMN exon 7 inclusion in SMA patient 
fibroblasts.  Oligonucleotides which are complementary to regions containing exon 
splice suppressors have also been used to promote exon seven inclusion and 
increased full-length SMN mRNA and protein levels in human fibroblasts (Hua et al., 
2007). Antisense oligonucleotides administered intravenously in a mouse model 
expressing the human SMN2 gene caused an increase in SMN2 levels in the liver 
but not in the spinal cord (Hua et al., 2008). However delivery of oligonucleotides 
by intracerebroventricular injection was able to rescue tail and ear necrosis in a 
type III SMA mouse model (Hua et al., 2010). Furthermore delivery of 
oligonucleotides directly to the CSF increased the level of full length SMN2 in the 
brains of SMA mice by blocking intronic splice suppressors (Williams et al., 2009). 
Treated mice displayed improved self-righting abilities although they were still 
weaker than wild-type littermates.  
Oligonucleotides have also been used to modify SMN2 in order to make it more 
like SMN1, causing an increase in SMN1-like DNA in SMA fibroblasts (DiMatteo et al., 
2008). Bi-functional RNA has been used which can block an exonic splice repressor 
on SMN2 and can also recruit proteins that promote splicing (Baughan et al., 2006; 
Baughan et al., 2009). Intraventricular injection of this bi-functional RNA increased 
the lifespan of severe SMA mice. Small nuclear RNA has been developed which also 
corrects splicing of SMN2 following incorporation into the small nuclear 
ribonucleoprotein. This increases SMN levels in SMA mice however not to wild-type 
levels. RNA that drives transplicing has also been used to repair SMN2 by causing 
the endogenous RNA to be spliced with the therapeutic RNA to create the correct 
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RNA sequence. This led to increased SMN levels in both patient fibroblasts and SMA 
mice (Coady et al., 2007; Coady et al., 2008).  
 
1.2 Gene Therapy 
The principal of gene therapy is the introduction of nucleic acid to a cell or 
organism to treat or prevent a disease. This can be achieved by either the 
introduction of DNA or RNA in order to express a gene, or the introduction of 
interfering RNA to reduce the expression of a certain gene. Various different gene 
therapy systems have been developed to aid the delivery of nucleic acids into cells 
since negatively charged nucleic acid cannot easily pass into cells and is quickly 
degraded by nucleases in vivo. The main hurdles to efficient gene therapy are 
enabling nucleic acids to reach the target tissue and ensuring it is expressed once 
it gets there. Different vectors have been developed with this aim in mind and each 
has varied advantages and disadvantages.  
Different characteristics are needed for the treatment of different diseases due to 
different target tissues and different expression profiles needed. For example for 
neurodegenerative disorders gene therapy vectors must be able to reach the CNS 
and also must be able to transfect or transduce non-dividing cells. Furthermore it 
may be necessary for expression of the target gene to be long lasting in some 
diseases whilst still maintaining an appropriate safety profile. One major concern 
with some gene therapy vectors is safety following administration in humans, and 
this must be considered alongside the other characteristics of gene therapy vectors.  
Gene therapy vectors can be divided into two main types, viral and non-viral with 
many different subtypes in each group. The features of some of these vectors will 
be discussed in more detail below with particular focus on adeno-associated viral 
vectors and polymer nanoparticles.  
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1.2.1 Viral Vectors for Gene Therapy  
Various different viral vectors have been developed by harnessing the ability of 
naturally occurring viruses to enter cells and drive expression of the genes they are 
carrying. Viruses can be based on either RNA or DNA and can have different routes 
of internalisation and different methods of gene expression. 
 
1.2.1.1 Retroviral and Lentiviral Vectors 
Retroviruses use single stranded RNA that integrates into the host genome upon 
transduction. They can be characterised as simple or complex depending on the 
proteins they encode. Lentivirus is a type of complex retrovirus as it has additional 
genes within a double stranded RNA genome.. These viruses express the gag gene 
encoding structural proteins, pol gene encoding enzymes such as those for reverse 
transcription and the env gene encoding viral envelope proteins (Escors & Breckpot, 
2010). The viral genome also contains two long terminal repeats (LTR) required for 
reverse transcription and integration into the host genome. Simple retroviruses are 
unable to transduce non-dividing cells such as post-mitotic mature neurons, and are 
therefore unsuitable for treating neurological diseases (Lewis & Emerman, 1994). 
Retroviruses initiate transduction through host genome integration to cause 
persistent gene expression. This causes a risk of insertional mutagenesis but can be 
useful for tissue culture models and ex vivo applications. 
Lentiviral vectors can transduce both dividing and non-dividing cells and have 
therefore been used to transduce neuronal cells (Blomer et al., 1997; Bensadoun et 
al., 2000; Koerber et al., 2008). Lentiviral vectors have been derived from animals 
infected with viruses such as the human immunodeficiency virus, simian 
immunodeficiency virus, equine immunodeficiency virus, feline immunodeficiency virus 
and bovine immunodeficiency virus. To make these viral vectors safer the majority 
of the viral genome has been deleted which makes them less immunogenic and 
stops their ability to replicate (Dull et al., 1998; Zufferey et al., 1998). Other 
advantages of these viral vectors are their large packaging capacity for target 
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genes, and expression of up to 44 months due to stable integration into the host 
genome (Naldini et al., 1996; Blomer et al., 1997; Kordower et al., 2000; Deglon & 
Aebischer, 2002). 
Lentiviral vectors have been previously used to express the human SMN1 gene in 
SMA fibroblasts and in motor neurons of SMA mice. The LV vector used was 
pseudotyped with a rabies glycoprotein to enable retrograde transport of these 
vectors following intramuscular injection (Mazarakis et al., 2001; Azzouz et al., 2004).  
This demonstrates that LV vectors can successfully transduce motor neurons in vivo 
and the addition of different envelope proteins via pseudotyping can alter 
mechanisms of uptake. Lentiviral vectors are very useful for in vitro studies due to 
their high efficiency of transduction and long-term expression. These vectors also 
show promise in the clinic and 67 clinical trials are either completed or on-going 
using lentiviral vectors (Gene Therapy Clinical Trials Worldwide database, J. Gene 
Med (Edelstein, 2013)) including two trials aimed at developing therapies for 
Parkinson’s disease.  
 
1.2.1.2 Adenoviral Vectors 
Adenoviruses are small non-enveloped viruses with a linear double-stranded DNA 
genome. Following transduction this genome does not integrate into the host 
genome but is maintained as a linear episome, leading to transient expression 
(Hillgenberg et al., 2001). This transient expression is not ideal for treatment of long 
term neurological disorders without repeat administration. Adenoviral vectors were 
developed lacking non-essential viral genes following concerns over the 
immunogenicity of the vector however there was still an immune response to capsid 
proteins (Kochanek et al., 2001; Liu & Muruve, 2003; Sakhuja et al., 2003; McKelvey 
et al., 2004). These viral vectors have been shown to transduce cells of the CNS 
such as neurons and astroglia however toxicity leads to clearance of transduced 
cells (Thomas et al., 2001; Thomas et al., 2002; Candolfi et al., 2007). This has 
been utilised for the treatment of cancer but these vectors are not particularly 
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suitable for treatment of neurodegenerative disorders (Germano et al., 2003; 
Immonen et al., 2004).  
 
1.2.1.3 Adeno-associated Viral Vectors 
Adeno-associated viruses (AAV) are single-stranded DNA viruses which have been 
found in many animal species including humans and can cause stable expression 
without any known pathogenicity. Various different AAV have been isolated from 
human subjects (Blacklow et al., 1967) and presence of AAV DNA appears to be 
fairly common throughout human populations (Gao et al., 2004). The different types 
of AAV have been classified into serotypes based on lack of cross-reactivity to 
neutralizing antibodies. The difference between serotypes can be narrowed down to 
unique capsid proteins which confer differential receptor binding and tissue tropism. 
Interestingly by changing the expression of capsid proteins through DNA shuffling 
novel vectors can be produced with unique cellular uptake profiles (Koerber et al., 
2008). Chimeric or mosaic vectors can also be created by combining capsids of 
various serotypes. Furthermore pseudotyped vectors have been developed which 
consist of the genome for one serotype enclosed in the capsid from another 
serotype (Burger et al., 2004; Zincarelli et al., 2008). These vectors are particularly 
useful for studying the effect of different serotype capsids on transduction efficiency 
of various tissues.   
Different AAV serotypes display tropism for different tissue types, however there is 
some cross-over of the tissues targeted by various serotypes with all serotypes 
being able to transduce many cell types. Furthermore the route of delivery can also 
affect which tissues are transduced due to biological barriers, making it difficult to 
classify the transduction profile of AAV serotypes. Some studies have analysed the 
transduction profile of various AAV serotypes following intravenous injection in adult 
and neonatal mice (Zincarelli et al., 2008; Zhang et al., 2011). In summary many 
AAV serotypes transduce different tissues following adult IV administration with 
differing level of efficiency and stability of expression. Overall expression of 
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luciferase in adults revealed that AAV2, 3, 4 and 5 provided low expression, AAV1, 
6 and 8 produce moderate expression and AAV7 and 9 give high expression 
(Zincarelli et al., 2008). However bioluminescent in vivo imaging does not provide a 
clear understanding of which serotypes preferentially target different tissues. The 
three serotypes relevant to this thesis will be discussed in more detail below. 
Interestingly following transduction by AAV vectors the viral DNA is often not 
integrated into the host genome but is maintained episomally (Penaud-Budloo et al., 
2008). This has the benefit of avoiding the risks associated with insertional 
mutagenesis whilst still providing stable, long-term gene expression (Kaplitt et al., 
1994; Koeberl et al., 1997). Occasionally vector integration does occur which is 
often associated with small chromosomal rearrangements and integration into 
coding regions of the genome (Miller et al., 2002; Nakai et al., 2003; Donsante et 
al., 2007). However risk of insertional mutagenesis from AAV is thought to be low (Li 
et al., 2011).  
As previously mentioned AAV infection has been found in many human subjects 
which raises the issue of pre-existing immunity. If a patient already has neutralizing 
antibodies to a certain AAV serotype transduction efficiency may be low and 
treatment could cause an unwanted immune response. There appears to be 
variation between pre-existing immunity for different serotypes, with AAV2 and AAV5 
being associated with a high incidence of neutralizing antibodies. AAV7 and AAV8 
are considered to have low pre-existing immunity due to low human exposure to 
these serotypes which were isolated from non-human primates. It may be possible 
to avoid pre-existing immunity by changing the capsid proteins of AAV vectors.   
As with all gene therapy vectors the main hurdle to overcome is achieving a 
sufficient level of transduction in the target tissue for a therapy to be clinically 
relevant. Self-complementary vectors have been developed to increase the 
expression of AAV vectors. These have a duplication of the gene of interest within 
the vector which can re-anneal once inside the cell which removed the requirement 
of DNA synthesis by the host cell (McCarty et al., 2001). Self-complimentary vectors 
therefore can produce quicker and more efficient transduction.  
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1.2.1.3.1 Adeno-associated Virus Serotype 5 
AAV5 was isolated from a human penial wart and sequencing data revealed a 
relatively low consensus with other AAV serotypes (Bantel-Schaal et al., 1999; 
Chiorini et al., 1999). The reduced homology is particularly apparent in the capsid 
proteins suggesting that AAV5 may have a unique mechanism of cell entry. The 
structure of AAV5 was determined by cryo-electron microscopy and revealed a 
similar surface topology to AAV2 (Walters et al., 2004). Interestingly however these 
two serotypes do not bind to the same receptors for endocytosis; AAV2 binds 
heparin whereas AAV5 binds scalic acid to enter cells by endocytosis of clathrin-
coated pits (Kaludov et al., 2001; Bantel-Schaal et al., 2002).  
AAV5 can transduce various cell types with high efficiency and generally has a 
slower onset of expression than other serotypes (Zabner et al., 2000; Chen et al., 
2005a; Ogura et al., 2006). Interestingly AAV5 can transduce neurons and 
astrocytes efficiently following direct injection to the brain or dorsal root ganglia 
(DRG) (Davidson et al., 2000; Mason et al., 2010; Lin et al., 2011). Furthermore when 
directly injected into the brain AAV5 is able to spread through the CNS to 
transduce a greater area than other serotypes (Davidson et al., 2000; Lin et al., 
2011). The effect of serotype on the ability of viral vectors to transduce the brain 
was investigated by comparing three different pseudotyped vectors injected directly 
into regions of the rat brain (Burger et al., 2004). This study showed that the 
capsids of serotypes 1 and 5 enabled vectors to transduce larger areas of the rat 
brain than the capsid from serotype 2. This suggests that capsid proteins influence 
how well viral vectors can pass through tissue and can determine the distribution of 
transduction.    
 
1.2.1.3.2 Adeno-associated Virus Serotype 6 
AAV6 was isolated as a contaminant of laboratory stock of AAV5, its sequence is 
very similar to AAV1 apart from the left ITR and p5 promoter which is almost 
identical to AAV2. This suggests that AAV6 arose from a recombination between 
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AAV1 and AAV2. Despite some homology to AAV2, AAV6 has distinct characteristics 
and can transduce cells in the presence of serum from AAV2 transduced animals 
(Halbert et al., 2000). However AAV6 has an almost identical serology to AAV1 
suggesting that they are not technically separate serotypes but do have distinct 
biological properties.   
 
Like AAV2, AAV6 can bind to heparin sulphate polyglycans on the cell surface to 
initiate cell binding and internalisation. However AAV6 does not possess the same 
capsid residues that AAV2 uses to bind heparin. Sialic acid binding is also utilised 
by AAV6 and AAV1 for the transduction of some cells types. The heparin binding 
capabilities of AAV6 can be exploited for the purification of AAV6 during 
manufacture through the use of heparin columns.  
 
AAV6 has been shown to transduce skeletal muscle and the liver with high 
efficiency and a relatively quick onset of transgene expression peaking at around 4 
weeks. When injected intravenously to a mouse model of familial amyotrophic lateral 
sclerosis (ALS) AAV6 mediated widespread transduction of heart, liver and skeletal 
muscle, as well as transducing 3-5% of lower motor neurons (Towne et al., 2008). 
Furthermore AAV6 can also transduce motor neurons by retrograde transport 
following intramuscular injection, with efficient gene transfer to motor neurons being 
demonstrated following injection of AAV6 to the gastrocnemius muscle of primates 
(Towne et al., 2010). Interestingly intramuscular injection of AAV6 to a mouse model 
of ALS generated efficient transduction to individually targeted motor neuron pools 
however this was not sufficient to affect disease progression (Towne et al., 2011). 
This suggests that intramuscular injection of AAV6 may not be sufficient to rescue 
motor function in SMA.  
 
1.2.1.3.3 Adeno-associated Virus Serotype 9 
As mentioned earlier, AAV9 has been used to transduce spinal cord motor neurons 
following intravenous administration. AAV9-mediated expression of SMN in motor 
neurons ameliorates the SMA phenotype and extends lifespan in a mouse model. 
41 
 
AAV9 can successfully transduce neurons in the CNS following intravenous 
administration but can also strongly transduce cardiac tissue and skeletal muscle. 
Furthermore as mentioned above intramuscular injection of AAV9 has been shown 
to result in widespread transduction in the spinal cord and also peripheral tissues 
(Benkhelifa-Ziyyat et al., 2013). The reason for the unique transduction 
characteristics of AAV9 is likely to be due to variation in capsid surface regions. 
Specifically, the VR-I and VR-IV amino acids which form surface loops on AAV 
capsids are arranged into a unique conformation in AAV9, conferring a unique 
transduction phenotype to this serotype (DiMattia et al., 2012). AAV9 can enter 
many cell types through binding of unique capsid proteins to galactose (Bell et al., 
2012). Interestingly scAAV9 can also mediate transduction of motor neurons in 
neonatal macaques, which indicates that AAV9 may be successfully used in human 
patients (Foust et al., 2010). Furthermore fetal administration of AAV9 to macaques 
can also generate transgene expression in neurons in the central nervous system 
and also in the peripheral nervous system (Mattar et al., 2013). This raises the 
possibility of providing prenatal treatment for SMA which may be advantageous for 
the most severe cases.   
1.3 Non-viral Mediated Gene Therapy 
Various non-viral methods of delivering gene therapy have been developed with 
different ways of shielding DNA and gaining entry to the cell. One way of delivering 
DNA to cells is by forming a complex between DNA and a cationic polymer or a 
cationic lipid (Merdan et al., 2002). Another way of delivering DNA is by 
encapsulating the nucleic acid within a vesicle. These can be made with either lipids 
and are known as liposomes, or with polymers and are known as polymersomes.  
As with all gene therapy the limiting factor is transfection efficiency, to achieve a 
high efficiency vectors must overcome various biological barriers (Roth & Sundaram, 
2004). Many non-viral approaches have been developed in vitro however transfer to 
an in vivo setting is difficult. For example in vivo vectors must be able to arrive at 
the target tissue with the nucleic acid cargo intact, they must be able to enter cells 
and facilitate endosomal escape. Finally for delivery of plasmid DNA the DNA must 
42 
 
then travel through the cytoplasm and enter the nucleus before transfection can 
occur. Polymersomes show much promise for in vitro and in vivo gene therapy due 
to their favourable characteristics such as low toxicity, efficient cellular uptake, 
relatively high circulation time in vivo (Bach & Bianchi, 2003; Lomas et al., 2008; 
Massignani et al., 2009; Lee et al., 2011a; Rodriguez et al., 2013). However since 
polymersomes are still a relatively new technology there is still much 
characterisation and optimisation to be done before they can be used successfully 
to deliver gene therapy for SMA. 
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1.3.1 Polymersomes 
 
1.3.1.1 Formation of Polymersomes 
Polymersomes are hollow vesicles formed from block copolymers that mimic 
phospholipids that form vesicles in nature. Polymersomes are formed in aqueous 
conditions by utilising the hydrophobic effect. Using a block copolymer consisting of 
a hydrophobic part and a hydrophilic part means that when in contact with water 
the polymers will arrange in a way that shields the hydrophobic blocks from the 
water and leaves the hydrophilic blocks in contact with the water. The most 
entropically favourable structure for this is a bilayer with the hydrophobic blocks in 
the centre of the bilayer and the hydrophilic blocks either side. However a single 
bilayer leaves the end hydrophobic molecules exposed therefore the bilayer curves 
into more complex structures (Smart et al., 2008). Various different shapes can be 
formed such as hollow spherical vesicles as well and cylindrical and spherical 
micelles that do not have a hollow core. Many intermediate structures can also be 
formed. The propensity for a certain shape or structure to be formed is determined 
by various conditions including polymer concentration and rate of formation which 
can be controlled by temperature. The main factor influencing the structure formed 
upon self-assembly of block-copolymers is the relative sizes of the two blocks. In 
the formation of polymersomes the size of the block-copolymer affects how closely 
it can pack together and therefore the degree of curvature of the membrane and 
thus the article size generated. This enables the size of the particles produced to 
be controlled by controlling the block-copolymer length however there is usually still 
a relatively large size distribution of particles. 
Polymersomes can be produced by two general methods, solvent switch or film-
rehydration. The first method uses a solvent that both blocks of the copolymer can 
dissolve in, then the solvent is switched to an aqueous solvent in which only the 
hydrophilic polymer can be dissolved, driving the formation of vesicles. The second 
method uses a thin film of polymer which is then rehydrated by stirring of an 
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aqueous solvent. As polymer comes into contact with the solution bits of polymer 
breaks off into solution and vesicles are formed. Following polymersome production 
there are various techniques employed to reduce polydispersity and select 
polymersomes of a particular size. These methods include sonication, gel 
permeation chromatography and hollow fibre filtration.  
 
1.3.1.2 Polymersome Characteristics 
The advantage of using polymers to form vesicles is the large array of 
characteristics that can be inferred on the vesicle through polymer chemistry. An 
interesting and particularly useful property of polymersomes is the toughness of the 
membrane formed. Polymers used to make polymersomes are much longer than 
phospholipids used to make liposomes with a higher molecular weight. This means 
that when the polymersome membrane is formed the polymer chains interdigitate 
and tangle with each other (Battaglia & Ryan, 2006). This causes polymersomes to 
have much stronger membranes than liposomes meaning they are less likely to 
break and are less permeable, therefore they hold their cargo better (Discher et al., 
1999).  
The most important characteristic of polymersomes for in vivo applications is being 
able to avoid protein adsorption due to their hydrophilic bush exterior. Low protein 
adsorption enables polymersomes to avoid clearance from the blood stream by 
avoiding the immune system. Some polymers are known to have low protein 
adsorption, the most famous being poly(ethylene glycol) (PEG), also known as 
poly(ethylene oxide) (PEO) (Alcantar et al., 2000). Poly(2-(methacryloyloxy)ethyl 
phosphorylcholine) (PMPC) also has a very low non-fouling profile, suggesting that 
polymersomes made of this hydrophillic polymer will be non-toxic (Lewis, 2000; 
Chen et al., 2005b). By engineering polymersomes with a corona made up of a 
nonfouling polymer such as PEO or PMPC polymersomes can avoid detection by the 
immune system and have relatively high circulation times as well as low toxicity.  
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Polymersomes can also be made to be responsive to their environment by 
incorporating responsive polymers.  The pH sensitive polymer poly(2-
(diisopropylamino)ethyl methacrylate) (PDPA) has been used to produce 
polymersomes that break up at low pH enabling endosomal escape of encapsulated 
cargo (Du et al., 2005). PDPA is a hydrophobic polymer that becomes deprotonated 
on the tertiary amine at low pH. Interestingly it has a pKa of around 6.6 and is 
therefore hydrophobic at physiological pH but becomes hydrophilic at pH5 causing 
rapid dissociation of the polymersomes. Other polymers have been used to create 
polymersomes that are sensitive to temperature, oxidative species or hydrolysis. 
Liquid crystalline polymersomes have been shown to undergo controlled release of 
cargo upon increasing temperature to around 55°C however this is unlikely to have 
any in vivo applications. Controlled release can also be achieved by forming 
polymersomes with hydrolysable polymers that are degraded over a matter of hours 
or days (Ahmed & Discher, 2004a). Similarly forming polymersomes using a block 
copolymer with a hydrophobic block that can be oxidised to a hydrophilic block can 
also enable controlled release of encapsulated cargo. Photo-responsive 
polymersomes have also been created through encapsulation of dextran. These 
particles undergo membrane rupture upon exposure to UV light however the 
biological application for this is unclear (Kamat et al., 2010). 
Further to choosing polymers with specific characteristics to produce polymersomes, 
polymers can be decorated with functionalities that can confer other properties to 
the polymersomes. The hydrophilic polymer can be conjugated with various 
molecules either directly or through biotin-avidin interaction. Direct conjugation of a 
fluorophore to the block copolymer enables polymersomes to be fluorescently 
labelled to assist tracking of these particles in vitro and in vivo (Madsen et al., 
2011). Functionalizing polymers with biotin enables polymersomes to be formed 
which can be tagged with a variety of different moieties without changing the 
polymer chemistry (Weiss et al., 2007).  
Peptides can be added to the surface of polymersomes through conjugation to the 
hydrophilic polymer to affect the uptake profile of polymersomes. By attaching 
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peptides to the surface of polymersomes that recognise specific cell receptors, cell 
specific targeting can be achieved. This suggests that polymersomes can be 
targeted towards specific areas of interest and could enable crossing of the blood 
brain barrier to achieve CNS delivery. Tissue specific targeting of polymersomes 
would be very useful for gene therapy as this would reduce the risk of off-target 
affects and make therapy more specific. Furthermore polymersomes can be 
decorated with other peptides to improve their stealth properties and increase in 
vivo circulation times (Egli et al., 2011; Rodriguez et al., 2013). 
 
1.3.1.3 Biological Applications 
Polymersomes have a wide range of biological applications due to the flexible 
design and varied characteristics outlined above. Encapsulation of both hydrophilic 
and hydrophobic particles in the aqueous core and polymer membrane respectively 
allows polymersomes to be used as a delivery vehicle for many biomacromolecules 
such as antibodies and drugs as well as nucleic acids for gene therapy. 
Polymersomes have been used to encapsulate a combination of hydrophilic and 
hydrophobic cancer drugs with impressive tumour shrinking results (Ahmed et al., 
2006a; Ahmed et al., 2006b; Li et al., 2007; Chen et al., 2010b). Proteins and 
antibodies have also been encapsulated within polymersomes (Wang et al., 2012; 
Canton & Battaglia, 2013). Polymersomes can also be used for diagnostic purposes 
and in vitro applications through the delivery of fluorophores. 
 
1.3.1.4 Polmersomes for Gene Therapy 
Polymersomes can readily enter cells by endocytosis and can encapsulate nucleic 
acids in their aqueous core making them a promising vehicle for gene therapy. 
Antisense oligonucleotides and siRNA have been successfully encapsulated into 
polymersomes and have been delivered to cells leading to transduction (Kim et al., 
2009; Jin et al., 2010). Plasmid DNA has been encapsulated within PMPC-PDPA 
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polymersomes with an estimated 20% of DNA added to the solution being retained 
within the polymersomes (Lomas et al., 2007). Interestingly at weakly acidic pH the 
protonated tertiary amine groups of the PDPA block interact with the phosphate 
groups of DNA. This is thought to aid encapsulation by complexing the DNA to the 
block copolymer, before the pH is increased to form polymersomes. When the pH is 
increased to a neutral pH the formation of vesicles is unaffected by the relatively 
weak binding of DNA to PDPA and the DNA is trapped inside the lumen of these 
vesicles. Importantly these pH-sensitive polymersomes release around 90% of the 
encapsulated DNA when pH is dropped to around 6 and then increased again to 
neutral pH (Lomas et al., 2010). Poly(oligo(ethylene glycol) methacrylate) (POEGMA) 
has also been used to make a block copolymer with PDPA to form polymersomes. 
POEGMA-PDPA polymersomes have also been used to encapsulate plasmid DNA, and 
have been incorporated into large layer-by-layer capsules in order to achieve 
delivery of a large number of particles at one time (Lomas et al., 2011).  
Encapsulation and delivery of plasmid DNA by PMPC-PDPA polymersomes has 
resulted in efficient transfection of Chinese hamster ovary and human dermal 
fibroblast cells with a GFP reported plasmid (Lomas et al., 2007). 
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1.4 Aims of the Project 
The aim of this project was to develop potential therapies for SMA by investigating 
different viral and non-viral gene therapy vectors. Furthermore the effect of two 
potential disease-modifying genes was investigated. This project used 3 AAV vectors 
and polymersomes to investigate gene therapy for SMA. The project aimed to 
optimise encapsulation of DNA within polymersomes and assess their ability to 
mediate transfection. The ability of AAV5 to transduce CNS tissue following neonatal 
intravenous injection was investigated to determine whether this vector could be 
used for SMA gene therapy. AAV6 was used to overexpress hnRNP R in a mouse 
model of SMA with the aim of investigating whether this could rescue the disease 
phenotype. The effect of PTEN silencing on SMA through AAV9 expression of siRNA 
was also investigated to determine whether PTEN silencing could improve survival in 
SMA. 
The aims of the project can be summarised as follows: 
i. Optimise and validate polymersomes as a gene delivery vehicle to be 
used to express SMN plasmid DNA in vitro. 
ii. Assess the ability of AAV5 to transduce CNS tissue following neonatal 
intravenous delivery in wild-type mice. 
iii. Investigate whether AAV6-mediated overexpression of hnRNP R could 
ameliorate the phenotype of an in vivo mouse model of SMA. 
iv. Determine whether silencing PTEN through AAV9-mediated expression of 
siRNA could increase the lifespan of a mouse model of SMA. 
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Chapter 2  
 
MATERIALS & METHODS 
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2.1. Materials 
 
2.1.1. Polymer Synthesis 
Poly(2-(methacryloyloxy)ethyl phosphorylcholine)25-b-poly(2-(diisopropylamino)ethyl 
methacrylate)70 (PMPC-PDPA) and rhodamine 6G labelled PMPC-PDPA (Rhd-PMPC-
PDPA) were kindly synthesized by Dr Jeppe Madsen and Dr Nicholas Warren by 
atom transfer radical polymerisation as previously reported (Du & Armes, 2005; 
Madsen et al., 2011). 
 
2.1.2. DNA Preparation 
pCS2+hSMN and pGL4.13[luc2/SV40] (Promega) plasmids were prepared using 
Qiagen mega prep kit (Qiagen). They were further desalted before use with 
polymersomes by ethanol precipitation. 
 
2.1.3. PTEN siRNA 
To silence PTEN a 19 nucleotide sequence targeting exon 1 of mouse PTEN was 
used to generate a stem-loop-stem shRNA. The sequences used were as follows:  
 
- siPTEN: 5’-AGATGAGAGACGGCGGCGG-3’ 
- scrambled-siPTEN: 5’-CCCTCTATCGCGCCCTGCT-3’ 
 
 
2.1.4. Viral Vectors 
The production of all viral vectors used for in vivo studies was out-sourced; details 
of companies used and viral titres are as follows:   
Table 2.1 List of viral vectors used 
Virus Promoter Production Company Titre 
AAV6-hnRNP R-HA CMV Virapur 4.0E12 vp/ml  
AAV6-GFP CMV Virapur 1.2E13 vp/ml 
AAV5-CMV-hrGFP CMV AMT Biopharma 1.23E13 gc/ml 
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AAV5-CAG-GFP CAG AMT Biopharma 3.30E12 gc/ml 
AAV9-siPTEN CMV University of North Carolina 1.5E12 vp/ml 
AAV9-scrambled-siPTEN CMV University of North Carolina 2.0E12 vp/ml 
vp - virus particles, gc – genome copies 
 
2.1.5. Protein Extraction and Analysis 
Lysis of cells was performed using cytoplasmic and nuclear lysis buffer containing 
50mM Tris-HCl, 150mM NaCl, 2mM EDTA (ethylenediaminetetraacetic acid, Melford), 
1% Igepal CA630  (Sigma) and 0.1% SDS (sodium dodecyl sulphate, Sigma). 
Extracted protein samples were added to loading buffer (10ml 4x stock: 4ml glycerol 
(Sigma), 2ml 10% SDS, 0.25mg bromophenol blue (Sigma), 2.4ml stacking gel 4x 
buffer (see below), and 0.5ml b-mercaptoethanol (Invitrogen)) before being 
denatured. Polyacrylamide gels were prepared using 4x separating gel buffer (1.5 M 
Tris base, 13.87mM SDS, pH 8.8) and 4 x stacking gel buffer (0.5 M Tris base, 13.87 
mM SDS, pH 6.8), along with 30% acrylamide (Geneflow), ammonium persulfate 
(Sigma) and TEMED (tetramethylethylenediamine, Sigma). Transfer buffer used for the 
transfer of proteins onto a polyvinylidene difluoride (PVDF) membrane (Millipore) 
contained 25mM Tris, 192mM Glycine and 10% v/v methanol. Membrane washes 
were carried out in TBS-T (0.137 M NaCl, 25.92 mM Tris base, 0.1% Tween20 
(Sigma), pH 7.6 and membranes were incubated in blocking solution before addition 
of antibodies (TBS-T with 5% w/v dried skimmed milk). 
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2.1.6. Antibodies 
Table 2.2 List of antibodies used  
Target Protein Host Supplier Cat No. Use 
Primary Antibodies     
SMN Mouse  BD 610646 WB + IF 
α-Tubulin Mouse Calbiochem CP06 WB 
GFP Rabbit Invitrogen A11122 IHC + IHF 
NeuN Mouse Millipore MAB377 IHF 
GFAP  Mouse Sigma G3893 IHF 
PTEN Mouse Santa Cruz sc-7974 IHF 
CGRP Mouse Abcam Ab47027 IHF 
GFP-TRITC Goat Acris R1091T IHF 
Secondary Antibodies     
Mouse-HRP Goat Bio-Rad 170-6516 WB 
Rabbit-FITC Goat Jackson 111-095-003 IF + IHF 
Mouse-A594 Goat Invitrogen A1105 IF + IHF 
Mouse-A350 Goat Invitrogen A11045 IHF 
WB - Western blot, IHC – immunohistochemistry, IF - Immunofluorescence, IHF - 
immunohistofluorescence. 
2.1.7. Spectrophotometry 
Assays requiring microplate reader for UV/Vis absorbance measurements or 
luminescence measurements were performed using a FLUOstar Omega plate reader 
(BMG Labtech). Fluorescence measurements were recorded using a Varian Cary 
Eclipse spectrofluorimeter.  
 
2.2. In Vitro Experimental Methods 
 
2.2.1. Cell Lines and Cell Culture 
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HEK293T cells (human embryonic kidney cell line immortalized by the adenoviral 
E1A/E1B protein and expressing the SV40 large T antigen) were used for uptake 
assay, toxicity assay and transfection. GM03813 fibroblasts derived from an SMA 
type 1 patient (Coovert et al., 1997) (Coriell Cell Repository) were also used for 
transfection. For HEK293T cells, Dulbecco’s Minimum Essential Medium (DMEM with 
4.5 g/L Glucose, L-glutamine, without Na Pyruvate, Lonza) was used and for 
fibroblast cell line Minimum Essential Medium Eagle (MEME without L-glutamine, 
Sigma M5650) was used. Both were supplemented with 10% fetal calf serum (FCS, 
Biosera), and 100 U/ml of penicillin and 100 μg/ml streptomycin (penicillin G 
sodium and streptomycin sulphate in 0.85% saline, Invitrogen). MEME was also 
supplemented with 1% L-glutamine (200mM, Sigma). 
 
 
2.2.2. Polymersome Production 
First PMPC25-PDPA70 polymer was weighed and dissolved in pH2 PBS to make a 
starting polymer concentration of 10mg/ml, usually a starting volume of between 
4ml and 6ml of polymer solution was used to produce polymersomes. The solution 
was then filter sterilised and sonicated for 15 minutes to ensure complete 
dissolution of the polymer. A syringe pump was used to increase the pH by 
addition of 0.5M NaOH with constant stirring. Plasmid DNA was then added at pH6 
again using the syringe pump, to give a final DNA concentration of 50µg/ml, before 
further addition of 0.5M NaOH until pH7.4 was reached. At this point the solution 
would appear turbid due to the formation of polymersomes. The solution was then 
sonicated for 30 minutes in order to reduce polydispersity.  
To purify polymersomes by size the solution was separated into 1ml aliquots and 
centrifuged at various speeds for 20 minutes before re-suspending the pelleted 
polymersomes in PBS.  To separate different sized polymersomes (section 3.2.1.4) 
the polymersome solution was first centrifuged for 20 minutes at an r.c.f of 500 x 
g, the supernatant was then removed and centrifuged again for 20 minutes at an 
r.c.f of 2000 x g. This process of removing the supernatant and centrifuging again 
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was repeated at an r.c.f of 5000, 10000, 15000 and 20000 x g, all for 20 minutes 
(table 2.3). Following each centrifugation the pelleted polymersomes were re-
suspended in PBS and polymer concentration, DNA concentration and particle size 
was measured.  
Table 2.3 Centrifugations to separate polymersomes by size 
 Sample Centrifuge Speed (r.c.f) Time (mins) 
1 Initial solution of polymersomes 500 x g 20 
2 First supernatant 2000 x g 20 
3 Second supernatant 5000 x g 20 
4 Third supernatant 10000 x g 20 
5 Fourth supernatant 15000 x g 20 
6 Fifth supernatant 20000 x g 20 
2.2.3. Polymersome Characterisation 
To characterise the size of nanoparticles produced the polymersome solution was 
diluted in PBS and size was measured using dynamic light scattering (DLS) (Malvern 
Zetasizer Nano ZS).  To measure concentration fluorescence of rhodamine-labelled 
polymer was measured using a Varian Cary Eclipse spectrofluorimeter. A calibration 
curve was made using serial dilutions of Rhodamine-PMPC-PDPA. Each sample was 
diluted before measuring fluorescence with excitation at 540nm and measurement at 
560nm.  
 
2.2.4. Encapsulation Assessment 
PicoGreen assay (Quant-iT PicoGreen, Invitrogen) was used to measure the 
concentration of plasmid DNA encapsulated within the polymersomes as to the 
manufactures guidelines. For calibration curve serial dilutions of the original sample 
before purification was used. Polymersomes were centrifuged at an r.c.f of either 
5000, 10000 or 20000 x g (section 3.2.1.3) and the pelleted polymersomes were re-
suspended in PBS in order to remove any free DNA. In the presence of DNA the 
PicoGreen reagent fluoresces. Fluorescence was measured at 520nm after excitation 
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at 485nm. To determine levels of DNA encapsulation in different sized 
polymersomes (section 3.2.1.4) polymersomes were centrifuged as outlined in section 
2.2.2, and PicoGreen assay was performed following re-suspension of pelleted 
polymersomes. 
 
2.2.5. Toxicity Assay 
Reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT, 
Sigma) by cellular dehydrogenases was used to quantify the number of living cells. 
MTT (pale yellow substrate) is reduced in metabolically active cells to form insoluble 
purple formazan crystals. Cells were grown in 24 well plates, when they came to be 
assayed the growth media were removed, 1ml of 5mg/ml MTT was added to each 
well  and the cells were incubated at 37ºC for 45 minutes. The MTT solution was 
then removed and 100µl acidified isopropanol was added to solubilize the formazan 
crystals. The plate was shaken for two minutes before the solution was transferred 
to a 96 well plate to measure the absorbance. Absorbance was determined at 540 
nm and referenced at 630nm.  
 
 
2.2.6. Luciferase Assay 
Cells were grown in 24-well plates and transfected with luciferase. When they were 
to be assayed the cell growth media was removed, the cells were washed and then 
resuspended in 100µl PBS. The cell solution was transferred to a 96-well plate and 
100µl Luciferin substrate was added (Bright-Glo Luciferase Assay System, Promega) 
and luminescence was recorded using a FLUOstar Omega plate reader (BMG 
Labtech).  
 
2.2.7. Real-time Quantitative-PCR 
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Cells were harvested at the appropriate time and RNA was extracted using the SV-
total RNA extraction system (Promega) to the manufacturer’s guidelines. The 
concentration of extracted RNA was then measured using NANODROP1000.  cDNA 
was synthesized from the RNA by reverse transcription using the super-script III first-
strand synthesis system (Invitrogen). For QPCR 12.5ng cDNA was added to 10µl 2x 
SYBR Green Master Mix (Aligent) along with the appropriate forward and reverse 
primers and H20 to make a final volume of 20mL. MX3000-P Real-time PCR system 
was used to perform the QPCR using the following program:  
- 95°C 10 minutes 
- 95°C 30 seconds 
- 60°C 1 minute 
- 95°C 1 minute 
- 60°C 30 seconds 
- 95°C 30 seconds 
 
Signal intensity was analysed using the MX3000 software and expression values 
were normalized to GAPDH. 
Table 2.4 Primers used for QPCR 
Gene Primer Sequence Concentration 
SMN  Forward – 5’ TGCTGGCTGCCTCCATTT 3’ 
Reverse – 5’ GCATCATCAAGAGAATCTGGACAT 3’ 
150 nM 
150 nM 
GAPDH Forward – 5’ GGAAGCTCACTGGCATGGC 3’ 
Reverse – 5’ TAGACGGCAGGTCAGGTCCA 3’ 
300 nM 
300 nM 
 
2.2.8. Western Blot 
Protein lysates were collected at the appropriate time using nuclear and cytoplasmic 
lysis buffer supplemented with complete protease inhibitor cocktail (Roche).  Protein 
concentration was then determined by Bradford assay.  For HEK cell transfection 
5µg protein per sample was used, for SMA fibroblast transfection 15ug protein per 
40 cycles 
Dissociation curve 
57 
 
sample was used. Protein samples were denatured in loading buffer by heating at 
95ºC for 5 minutes before being loaded on to a 10% SDS-polyacrylamide gel.  The 
gels were electrophoresed in Tris/Glycine/SDS running buffer at 50V for 30 minutes 
then 1-1.5 hours at 120V. For immunodetection proteins were transferred onto a 
PVDF membrane (Millipore). The membrane was placed in 100% methanol before 
being immersed in transfer buffer. The proteins were transferred onto the membrane 
in cold transfer buffer at 250mA for 1 hour, or at 40mA overnight at 4ºC. 
Membranes were then blocked in blocking buffer for 30 minutes at room 
temperature with agitation before being probed with antibodies. Primary antibody 
solutions were prepared in blocking buffer and secondary antibody solutions were 
prepared in TBST. Mouse primary antibodies against SMN and α-tubulin were diluted 
at 1:5000 and incubated at room temperature for two hours with agitation. A goat 
secondary anti-mouse-HRP antibody was used at a dilution of 1:2000 and incubated 
for 1 hour at room temperature with agitation. Between antibody incubations the 
membranes were washed three times for ten minutes in TBST at room temperature 
with agitation to remove any un-bound antibody. The proteins were visualized using 
the ECL Plus chemiluminescence detection kit (GE Healthcare) for HRP (horseradish 
peroxidase). The chemiluminescence was visualized using the G-BOX Image Capture 
System (G:BOX, Syngene), this was also used for image capture and densitometric 
analysis using the GeneSys software (GeneSnap and GeneTools, GeneSys software, 
Syngene). 
 
2.2.9. Immunofluorescence 
Immunofluorescence staining was performed on fibroblasts after transfection with 
SMN plasmid DNA to investigate transfection by polymersomes. Cells were plated 
onto glass coverslips in 6-well plates at a density of 5x104 cells per well. 72 hours 
after transfection, the cells were fixed by incubating them in 4% PFA in PBS at 
room temperature for 15 minutes.  Cells were washed with PBS then incubated with 
blocking solution (0.5% Triton TX-100 (Sigma), 5% normal goat serum in PBS) for 
30 minutes at room temperature. Blocking solution was then removed and cells 
were incubated with anti-mouse SMN antibody (BD, 610646) diluted at 1:1000 in 
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PBS for 2 hours. After 3x 10 minute PBS washes the cells were incubated with anti-
mouse fluorescent secondary antibody with an Alexafluor 594 conjugate (Invitrogen 
A1105) diluted at 1:200 in PBS for 1 hour at room temperature in the dark. Cells 
were washed a further 3 times for 10 minutes in PBS and were then mounted on 
glass slides using Vectashield mounting medium with DAPI. Images were taken with a 
fluorescence microscope (ZEISS) using OpenLab software (Improvision) at 63x 
magnification and were analysed using ImageJ software.  
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2.3. In Vivo Experimental Methods 
 
2.3.1. Breeding and Genotyping of Transgenic Mice 
For all in vivo studies, FVB.Cg-Tg(SMN2*delta7)4299Ahmb Tg(SMN2)89Ahmb 
Smn1tm1Msd/J SMNΔ7 mice (The Jackson Laboratory stock 005025) were used. These 
are triple mutant mice on a FVB background; they have two transgenes inserted, 
the full-length human SMN2 gene and a second copy of the human SMN gene 
lacking exon 7. The mice are also lacking the murine Smn gene (Le et al., 2005). 
All mice were maintained in a controlled facility in a 12-hour dark-light photocycle 
with free access to food and water. All in vivo experimental work was performed in 
accordance to the UK Home Office Animals (Scientific Procedures) Act 1986.  
 
Carrier animals were used for breeding, and the offspring were genotyped 
immediately after birth by PCR to detect presence of the transgene. Tail clips were 
taken at the day of birth and incubated in 15µl DNA extraction buffer (DNA 
extraction solution 1.0. Epicentre Biotechnologies) for 1 hour at 65ºC and then 
inactivated at 98ºC for 5 minutes. The PCR reaction was then performed using this 
DNA. Three primers were used recognizing Smn with two different reverse primers 
specific for either the wild-type gene, or the mutated gene.  
 
Table 2.5 Primers used for genotyping 
Primer Sequence Concentration 
Smn Forward 5’ CTCCGGGATATTGGGATTG 3’ 1.34 µM 
Smn Wild-Type Reverse 5’ TTTCTTCTGGCTGTGCCTTT 3’ 1.34 µM 
Smn Targeted-Mutation Reverse 5’ GGTAACGCCAGGGTTTTCC 3’ 0.5 µM 
 
The PCR reaction consisted of 1ul of template, 1.34µM of forward primer and 
1.34µM or 0.5µM of either Wild-type or Targeted-Mutation reverse primer, 5µl PCR 
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Mix (5x FIREPol Master Mix, Solis BioDyne) and H2O to a final volume of 25µl. The 
PCR program was as follows: 
- 95°C 3 minutes 
- 95°C 30 seconds 
- 52°C 30 seconds 
- 72°C 30 seconds 
- 72°C 7 minutes 
- 10°C forever 
 
The PCR product was electrophoresed on a 1.5% agarose gel with 0.5µg/uL 
ethidium bromide at 140V for 30 minutes. Wild-type animals were expected to have 
one band at 800bp. Homozygous transgenic animals were expected to have one 
band at 500bp and hemizygous carriers were expected to have two bands, one at 
800bp and one at 500bp. Bands were visualised on a GENi imaging system 
(Syngene).  
 
2.3.2. Recruiting Experimental Mice 
For the AAV6-hnRNP R study (chapter 4) and the AAV9-siPTEN study (chapter 6) 
litter mates were split equally between treatment groups when possible. For the 
AAV5-GFP study (chapter 5) wild-type litter mates of the SMNΔ7 mice were used. 
The sex of the recruited mice was not matched between groups as this was not 
possible without further PCR which time constraints did not permit prior to injections 
at post-natal day one. 
Power analysis was performed using GraphPad StatMate 2 software to determine the 
cohort size for the AAV6-hnRNP R study and the AAV9-siPTEN study.  This analysis 
indicated a total sample size of 10 per group was necessary to detect effects of 
25% on survival (two-tailed) with a power of 80%. However for the AAV6-hnRNP R 
35cycles 
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study the experiment was curtailed at n=7 for the AAV6-hnRNP R group and n=5 for 
the AAV6-GFP group due to the initial findings. 
 
2.3.3. Viral Vector Delivery 
Animals were injected in the facial vein the day after birth (post-natal day 1) under 
gas anaesthesia (IsoFlo, 100% w/w isoflurane inhalation vapour, liquid, Abbott) using 
anaesthesia apparatus (Burtons). A 10µl 33-gauge Hamilton syringe (ESS Lab) was 
used to inject 10µl of viral vector solution to each animal (see table 2.5 for dose 
administered). After injection animals were left a few minutes to recover before 
being rolled in sawdust from their cage and returned to the cage with their mother.   
Table 2.6 Viral vector dose administered 
Virus Titre Dose 
AAV6-hnRNP R-HA 4.0E12 vp / ml  4.0E10 virus particles 
AAV6-GFP 1.2E13 vp / ml 1.2E11 virus particles 
AAV5-CMV-hrGFP 1.23E13 gc / ml 1.23E11 genome copies 
AAV5-CAG-GFP 3.30E12 gc / ml 3.30E10 genome copies 
AAV9-siPTEN 1.0E12 vp / ml 1.0E10 virus particles 
AAV9-scrambled-siPTEN 1.0E12 vp / ml 1.0E10 virus particles 
   
2.3.4. Behavioural and Clinical Assessment 
Mice were weighed and assessed for motor ability daily as well as being scored for 
signs of distress. Motor ability was assessed using tests characterised previously (El-
Khodor et al. 2008). Righting reflex was assessed by placing animals on their backs 
and assessing whether they could turn-over onto their front within 30 seconds. For 
distress scoring four parameters were taken into account and scored, these scores 
were then combined to give an overall distress score. The parameters were as 
follows: appearance, provoked behaviour, percentage weight loss from peak body 
weight and hind-limb score. 
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2.3.5. Tissue Collection 
Mice were euthanized by intraperitoneal injection of 500mg/kg of sodium 
pentobarbital (sodium pentobarbital, 20% w/v solution for injections, JML) when the 
mice were deemed ready for sacrifice.  
For histological analysis intracardiac perfusion of cold PBS containing 5 units/mL 
Heparin (2000 units/mL heparin, Sigma) was immediately performed followed by 
perfusion with 4% PFA using an in vivo perfusion system (AutoMate Scientific). 
Organs were then collected and incubated overnight in 4% PFA at 4ºC. Spinal cords 
and brains were further incubated in 30% sucrose in PBS for at least one day 
before being cryoembedded in optimum cutting temperature medium (OCT, Dako). 
Muscle tissue was stored in PBS with NaN3 before being paraffin embedded and 
sectioned at 8µm. 
 
2.3.6. Histological Analysis 
Lumbar spinal cords were sectioned at 20µm and brains were sectioned at 40µm 
using a Lycia cryostat and mounted onto slides. To analyse AAV5 transduction 
efficiency 1 in 5 slides were taken throughout the brain and lumbar spinal cord for 
analysis. This equated to between 10 and 30 lumbar spinal sections being analysed 
per animal and 13-16 brain sections analysed per animal.  
 
2.3.6.1. Immunohistochemistry  
For the AAV6-hnRNP R study (chapter 4) total motor neuron counts were 
determined by staining sections for Nissl. Sections were incubated in xylene for 5 
minutes before being hydrated through 100%, 95% and 70% ethanol. Sections were 
then washed in H20 before being incubated in 0.1% Cresyl Fast Violet (BDH). After a 
brief wash in H20 sections were differentiated in 95% ethanol for up to 15 minutes 
(depending on the intensity of staining). The sections were then dehydrated in 
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100% ethanol for 1 minute and then incubated in xylene for 5 minutes before 
being mounted onto cover slips using DPX. The motor neurons were counted under 
a light microscope with help from Dr. K. Ning who was blinded to the treatment 
groups. Motor neurons were identified by their size and morphology.  
Transduction of cells of the brain and spinal cord were assessed by 
immunohistochemistry to detect cells expressing GFP protein. Vectastain ABC kit 
(Vector) was used for blocking solutions and secondary antibodies whilst DAB 
peroxidase substrate kit (Vector) was used to visualise the staining. Tissue was first 
incubated in 2% hydrogen peroxide in methanol for 20 minutes to block 
endogenous peroxidase. Sections were then washed in H20 for 1 minute followed by 
TBS for 5 minutes. Slides were then incubated with normal serum in TBS for 30 
minutes at room temperature to block any non-specific binding. Slides were then 
incubated with a polyclonal rabbit antibody against GFP (Invitrogen) at a dilution of 
1:500 in TBS for 1 hour at room temperature. After this incubation sections were 
washed twice for 5 minutes with TBS before being incubated with the biotinylated 
secondary antibody for 30 minutes at room temperature. Cells were then washed 
again for 2x 5 minutes in TBS before being incubated with the ABC reagent for 30 
minutes at room temperature. The slides were washed again for a further 2x 5 
minutes in TBS then incubated in diaminobenzidine (DAB) at room temperature for 
10 minutes. Finally cells were washed in H20 for 5 minutes before being dehydrated 
through 70%, 95% and absolute ethanol, and then placed in xylene before being 
mounted with coverslips using DPX. Slides were then analysed using an Olympus 
BX61 microscope with Cell^R (Olympus) software. 
 
2.3.6.2. Immunofluorescence 
Immunofluorescence was used to stain for neuronal or astrocyte markers (NeuN and 
GFAP respectively) as well as for GFP and PTEN. Slides were washed 3 times for 10 
minutes with PBS before being incubated with 5% normal goat serum (NGS) and 
0.5% Triton X-100 (Sigma) in PBS for 2 hours at room temperature. For the AAV5-
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GFP study (chapter 4) two primary antibodies were then incubated together, rabbit 
antibody against GFP (Invitrogen) alongside either a mouse antibody against GFAP 
(Sigma) or mouse antibody against NeuN (Millipore), all diluted 1:500 in PBS and 
incubated overnight at 4ºC. Sections were then washed three times in PBS before 
secondary antibodies were added. Secondary antibodies used were a goat FITC-
conjugated anti-rabbit antibody (Jackson), and a goat Alexafluor 594-conjugated 
anti-mouse antibody (Invitrogen). Secondary antibodies were diluted 1:200 in PBS 
and incubated at room temperature for 1 hour before being washed in PBS 3 times 
for 10 minutes.  
For the AAV9-siPTEN study (chapter 5) spinal cord sections were stained with a 
rabbit primary antibody against CGRP diluted at 1:500 and a goat Alexa-Fluor594-
conjugated anti-mouse antibody as described above. CGRP-positive motor neurons 
were counted with help from Dr. Ke Ning who was blinded to treatment groups. To 
assess transduction and PTEN depletion in the spinal cord triple 
immunofluorescence was performed. Sections were stained with a mouse antibody 
against PTEN (Santa Cruz), a goat antibody against GFP with a TRITC conjugate 
(Acris) and a rabbit antibody against CGRP (Abcam). These primary antibodies were 
diluted 1:200 and incubated overnight at 4ºC. Secondary antibodies used were a 
goat Alexafluor 350-conjugated anti-mouse antibody (Invitrogen) and a goat FITC-
conjugated anti-rabbit antibody (Jackson). These secondary antibodies were diluted 
1:200 and incubated at room temperature for 1 hour. Washing and blocking steps 
were performed as detailed above.  
Slides were mounted with Vectashield hard-set mounting medium with DAPI (Vector 
laboratories). Images were taken with a fluorescence microscope (ZEISS) using 
OpenLab software (Improvision) at 63x magnification and were analysed using 
ImageJ software. Confocal microscope images were taken using a Leica SP5 
microscope system.  
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RESULTS 
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Chapter 3  
 
Polymersomes as Gene Therapy Vectors 
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3.1 Introduction 
Polymersomes are designed to mimic vesicles found in nature using block 
copolymers rather than phospholipids to create a sphere consisting of a polymer 
membrane and a hollow core (Discher et al., 1999). Vesicles form in aqueous 
conditions when a block copolymer consists of a hydrophilic block and a 
hydrophobic block. The hydrophobic block minimises contact with water molecules 
by being in close proximity to other hydrophobic blocks, whilst the hydrophilic block 
repels other blocks in order to be in contact with water (Tanford, 1979). This 
behaviour causes a membrane to be formed, with the need for the hydrophobic 
blocks at the end of the membrane to be shielded from water causing curvature of 
the membrane, forming vesicles, spherical micelles and tubular micelles (Discher & 
Eisenberg, 2002). The propensity of block copolymers to form spherical or tubular 
micelles or vesicles is determined by the ratio between the soluble and insoluble 
blocks, or the hydrophilic and hydrophobic blocks. Therefore the structures formed 
can effectively be tuned by controlling the respective lengths of each part of the 
copolymer. The block-copolymers used to form polymersomes have a higher 
molecular weight than phospholipids, and the long polymer chains naturally interlink 
with each other (Battaglia & Ryan, 2005) therefore the particles produced have 
more resilient membranes than liposomes, creating improved mechanical properties 
(Discher et al., 1999).  
As well as affecting the structure formed changing the polymers used to make up 
the block-copolymer can change how polymersomes can react to or interact with 
their environment. Polymersomes can be made to be responsive to various external 
stimuli such as hydrolysis (Ahmed & Discher, 2004b), oxidative species (Napoli et al., 
2004), temperature (Agut et al., 2010; Hocine et al., 2013) and pH (Du et al., 2005; 
Giacomelli et al., 2006). Furthermore the nature of the polymer used can affect how 
it interacts with cells and the circulation half-life of polymersomes in vivo. Here we 
use block-copolymer with a hydrophilic poly(2-(methacryloyloxy)ethyl 
phosphorylcholine) (PMPC) block which has impressive nonfouling properties (Lewis, 
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2000), coupled with a hydrophobic poly(2-(diisopropylamino(ethylmethacrylate) (PDPA) 
block that is pH sensitive (Du et al., 2005). 
PMPC-PDPA polymersomes have been shown to enter many cell types by 
endocytosis (Massignani et al., 2009). Once endocytosed the pH sensitive nature of 
these polymersomes causes disassembly in the acidic environment of the endosome 
(Lomas et al., 2008; Massignani et al., 2009). This dissociation of the polymersome 
into individual block-copolymer units releases approximately 1700 copolymer chains 
(for a 200nm polymersome) as well as any encapsulated cargo into the endosome, 
causing osmotic shock and disruption of the endosome (Lomas et al., 2008). This 
enables encapsulated molecules to escape the endosome and be released into the 
cytoplasm. The aqueous core of polymersomes enables the encapsulation of various 
biomacromolecules including antibodies, drugs, and nucleic acid (Ahmed et al., 
2006b; Lomas et al., 2007; Kim et al., 2009; Canton et al., 2013). Moreover the 
hydrophilic polymer brush of the polymersomes can be decorated with ligands such 
as peptides that can influence uptake and targeting to specific cell types ((Broz et 
al., 2005; Weiss et al., 2007; Egli et al., 2011)). Furthermore this hydrophobic 
membrane allows the encapsulation and delivery of hydrophobic molecules (Ahmed 
et al., 2006b; Li et al., 2007).  
The most efficient method of gene therapy is generally considered to be through 
the use of viral vectors. Viruses have evolved to enter cells and use the machinery 
of the nucleus to express their own genes therefore they are an ideal candidate for 
delivery of therapeutic genes. Although viral vectors used for gene therapy have 
modified genomes making them non-pathogenic and unable to replicate, they can 
still be detected by the immune system (Xiao et al., 2000). Furthermore since viral 
vectors are based on naturally occurring viruses many people harbour antiserum 
against certain serotypes of adeno-associated viruses (Chirmule et al., 1999). The 
presence of antiserum against a viral vector can reduce transgene expression and 
may cause unwanted side effects. Furthermore generation of antibodies following 
administration of viral vector mediated gene therapy will reduce the effect of repeat 
delivery (Mastakov et al., 2002). Therefore it may be useful to develop non-viral 
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methods of delivering gene therapy that can avoid immune response. Polymersomes 
have previously been used to encapsulate DNA and deliver it to cells to cause 
efficient transduction (Lomas et al., 2007).  
Polymersomes are a relatively new technology with only a limited amount of 
research published regarding plasmid DNA encapsulation. Therefore, much 
optimisation is required to achieve a standardised method of production of 
nanoparticles with high encapsulation efficiency. Various methods of polymersome 
production were trialled before deciding on the method detailed in section 3.2.1.1 
using a syringe pump and magnetic stirrer. The ability of these nanoparticles to 
efficiently encapsulate plasmid DNA and cause transfection then needed to be 
verified and optimised. Therefore various methods of encapsulating plasmid DNA 
and improving encapsulation and transfection efficiency were tested before using 
the purification by centrifugation method detailed below.  
This aim of this section was to optimise encapsulation and transfection efficiency of 
PMPC25-PDPA70 polymersomes and test their ability to deliver gene therapy for SMA. 
Here centrifugation was used to sort polymersomes by size and investigate the 
effect of particle size on encapsulation. Furthermore polymersomes were used to 
deliver a reporter luceriferase gene in HEK293T cells and to deliver SMN plasmid 
DNA to an in vitro model of SMA.  
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3.2 Results 
 
3.2.1 Polymersome Characterisation 
 
3.2.1.1 Cell Viability Following Incubation with Polymersomes 
Polymersomes were produced by pH switch. Briefly the PMPC25-PDPA70 copolymer 
was dissolved at pH2 before being raised to pH6 using a syringe pump to control 
addition of NaOH whilst the solution was stirred using a magnetic stirrer. At pH6 
plasmid DNA was added to the solution; at this point the polymers are still 
completely dissolved. NaOH was again added until the solution reached pH7.4 by 
which point the PDPA block would become deprotonated and thus become 
hydrophobic, resulting in polymersome formation. All characterisation experiments 
were performed with polymersomes encapsulating luciferase plasmid DNA. This is to 
control for any affect the plasmid may have on the polymersome formation, size 
distribution or toxicity. Furthermore all characterisation experiments were performed 
using polymersomes containing 10% rhodamine-labelled PMPC-PDPA, which enabled 
the polymer concentration to be easily measured, as well as uptake to be assessed 
by fluorescent microscopy.  
We first aimed to assess how polymersomes affected cell viability and to ascertain 
the ideal working concentration to use. To this end we carried out an MTT assay 
following incubation of HEK293T cells with polymersomes. Rhodamine-labelled PMPC-
PDPA polymersomes encapsulating luciferase DNA were produced as described 
earlier and HEK293T cells were treated with six different concentrations of 
polymersomes. 48 hours later MTT assay was performed to measure cell viability. As 
polymer concentration increased cell viability decreased (fig. 3.1), becoming 
statistically significant at 1.0mg/ml (one-way ANOVA, Dunnett’s multiple comparison 
test). Cell viability of 80% was seen for a final polymer concentration of 0.5mg/ml, 
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therefore this was chosen as the maximum concentration to be used for further 
experiments.  
 
 
 
 
3.2.1.2 Uptake of Rhodamine-labelled Polymersomes by HEK293T Cells 
It has been shown that many cell lines can easily uptake PMPC-PDPA polymersomes, 
with the only cell type not displaying any uptake being red blood cells (Massignani 
et al., 2009). To demonstrate the uptake of polymersomes by HEK293T cells the 
cells were incubated with 0.5mg/ml of polymersomes containing 10% rhodamine-
tagged PMPC-PDPA. 48 hours later cells were washed and fixed with 4% PFA before 
being imaged by fluorescence microscopy. This study revealed that approximately 
100% of cells displayed fluorescence following treatment with fluorescent 
polymersomes, showing that these polymersomes are readily internalised by the 
cells (fig. 3.2). Furthermore fluorescence appeared to be spread throughout the 
cytoplasm with much less fluorescence seen in the nucleus. Uptake of rhodamine-
labelled polymersomes has previously been extensively studied, therefore this was 
Figure 3.1 HEK293T cell viability after treatment with Rhd-PMPC-PDPA. HEK293T cells were 
incubated for 48 hours with different amounts of Rhd-PMPC-PDPA polymersomes before MTT 
assay was performed. Cell viability decreased with high levels of polymersomes. n=3 ** p<0.01 
versus untreated control, one-way ANOVA with Dunnett’s multiple comparison test. 
** 
** 
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not further investigated here (Lomas et al., 2008; Massignani et al., 2009). Confocal 
microscopy of single HDF cells using pH-sensitive and non-pH-sensitive 
polymersomes demonstrated that PMPC-PDPA polymersomes are efficiently 
endocytosed and the fluorescent polymer is spread throughout the cytoplasm 
following endocytosis (Massignani et al., 2009). 
 
 
 
 
 
 
 
Figure 3.2 Uptake of rhodamine-labelled polymersomes in HEK293T cells. HEK293T cells were 
incubated with Rhd-PMPC-PDPA polymersomes for 48 hours before being fixed with 4% PFA and 
imaged for fluorescence. Cells treated with rhodamine-labelled polymersomes display fluorescence 
following uptake of the polymersomes. Scale = 20µm. 
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3.2.1.3 Encapsulation of Plasmid DNA in Polymersomes 
Production of polymersomes by the method detailed above (section 3.2.1.1) results 
in a polydisperse solution with a wide size distribution. Due to the relatively large 
size of plasmid DNA to the polymersome core we suspected that there may be 
polymersomes that are too small to encapsulate DNA, as well as micelles that are 
unable to encapsulate DNA due to their lack of lumen. Moreover we hypothesized 
that larger polymersomes would contain greater amounts of plasmid DNA. We thus 
sought a simple way of separating size fractions of polymersomes and hypothesized 
that in doing so we may also be able to select only the polymersomes containing 
high amounts of plasmid DNA. 
To test this hypothesis we first centrifuged polymersomes at an r.c.f of either 5000, 
10000 or 20000 x g. We then collected the resulting pellet of polymersomes, re-
suspended it, and measured the polymer concentration and DNA concentration. One 
advantage of centrifuging the polymersomes is that any free plasmid DNA remains 
in the supernatant, so the amount of encapsulated DNA can be easily measured. 
Furthermore the tough nature of polymersomes means that they are not damaged 
by centrifugation at high speeds. A third advantage of centrifugation is that it 
efficiently removes any micelles, which cannot contain DNA.  
Analysis of polymer concentration showed that at higher speed more polymer was 
pelleted, as expected (fig. 3.3 A). There was also an increase in the concentration 
of pelleted DNA (fig. 3.3 B), however when normalised to the amount of polymer 
pelleted the overall concentration of encapsulated DNA falls (fig. 3.3 C). A significant 
difference in the amount of encapsulated DNA was seen in polymersomes collected 
following centrifugation at an r.c.f of 5000 x g compared to those collected 
following centrifugation at an r.c.f of 20000 x g (p<0.01, one-way ANOVA) Therefore 
the polymersomes collected following centrifugation at slower speeds contain more 
DNA. The effect seen here was modest but significant and showed that plasmid 
DNA could be efficiently encapsulated within polymersomes and led us to 
investigate further the possibility of using centrifugation to separate polymersomes 
by size. 
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3.2.1.4 Using Centrifugation to Sort Polymersomes by Size 
To investigate further the use of centrifugation to separate different sized 
polymersomes we again made rhodamine-labelled polymersomes encapsulating 
plasmid DNA. The polymersome solution was centrifuged at an r.c.f of 500 x g, the 
supernatant removed and centrifuged again at an r.c.f of 2000 x g. The supernatant 
was removed and went through four further centrifugations at increasing speeds. 
Following each centrifugation the pelleted polymersomes were fully re-suspended 
and the particle size was measured by dynamic light scattering (DLS). Unfortunately 
the DLS software could not accurately determine the size of polymersomes 
collected following the first centrifugation at 500rcf. This may be due to the 
Figure 3.3 Encapsulation of plasmid DNA in polymersomes. Following polymersome 
formation, they were centrifuged at three different speeds. The polymer concentration (A) and 
DNA concentration (B) in the pelleted polymersomes was measured and used to calculate the 
amount of encapsulated DNA in each sample (C). n=3. * p<0.05, ** p<0.01, one-way ANOVA, 
Tukey’s multiple comparison post-hoc test.   
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presence of particles that are settling due to their large size, or due to the 
presence of non-spherical particles.  
Size distribution datashowed a decrease in size distribution following each 
centrifugation (fig. 3.4 A). Furthermore the mean particle diameter of polymersomes 
collected after centrifugation at an r.c.f of 2000 x g was significantly higher than 
the mean diameter of particles collected following centrifugation at an r.c.f of 10000 
x g (p<0.01, one-way ANOVA) (fig. 3.4 B). Therefore centrifugation is able to 
separate polymersomes by size, with the earlier, slow centrifugations pelleting 
polymersomes with higher average diameters than particles collected from later, 
faster centrifugations (fig. 3.4 B).Centrifugation does not completely separate size 
fractions in the solution but there is a clear shift towards smaller sized particles 
with higher speed centrifugations, suggesting that a high proportion of the largest 
particles have been removed following slow speed centrifugation.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Size sorting of polymersomes by centrifugation. Polymersomes were centrifuged at 
increasing speeds from 500 to 2000g. After each centrifugation step the supernatant was removed 
and centrifuged again at a higher speed. The polymersomes pelleted after each centrifugation were 
re-suspended and size was measured by DLS. A: size distribution by intensity for each centrifuge 
fraction. B: average particle diameter for each centrifuge fraction. Data shows mean diameter (nm) ± 
SEM. n=3. ** p<0.01 One-way ANOVA, Tukey’s multiple comparison post-hoc test. 
A B 
** 
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3.2.1.5 Size Dependent Encapsulation of DNA 
Once we had ascertained that centrifugation could separate different sized 
polymersomes we used the different polymersome fractions collected to assess how 
particle size affected the amount of encapsulated luciferase plasmid DNA. Using the 
same set-up described above (section 3.2.1.1), the polymersomes collected from 
each round of centrifugation were assessed for polymer concentration and DNA 
concentration. Analysis revealed that the amount of encapsulated DNA, when 
normalised to polymer concentration, was by far superior in the polymersomes 
centrifuged at the slowest speed (fig. 3.5 A). The concentration of encapsulated DNA 
then decreased in polymersomes collected after further centrifugation of the 
supernatants at increasing speeds. When the amount of encapsulated DNA 
(normalised to polymer concentration) is plotted against the average diameter of 
polymersomes measured above, a clear relationship can be seen between 
polymersome diameter and the amount of DNA that is encapsulated (fig. 3.5 B).  
Note that as in figure 3.4 the data from polymersomes collected after centrifugation 
at 500 rcf is not included in figure 3.5 as the size distribution data could not be 
accurately calculated (as mentioned in section 3.2.1.4). Furthermore there was a 
large amount of polymer left in the supernatant following the final centrifugation at 
20000 rcf that has been excluded from this analysis, this is expected to contain 
mainly micelles and small polymersomes as well as free DNA. 
 
 
 
 
  
Figure 3.5 Encapsulation of DNA in different polymersome fractions. Polymersomes 
encapsulating luciferase DNA were centrifuged at increasing speeds. After each 
centrifugation the DNA and polymer concentration of the pelleted polymersomes was 
measured (A). The amount of encapsulated DNA for each fraction was compared to the 
average particle diameter for that fraction (B). n=3. ** p<0.01, *** p<0.001, one-way ANOVA 
with Tukey’s multiple comparison post-hoc test. 
A B 
** 
*** 
** 
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3.2.2 Polymersomes as DNA Delivery System 
 
3.2.2.1 Luciferase Transfection with Polymersomes Sorted by Centrifugation 
To assess the transfection efficiency of encapsulated DNA, HEK293T cells were 
incubated with polymersomes collected following size sorting by centrifugation. The 
cells were incubated for 48 hours with 0.5 mg/ml of polymersomes collected after 
each centrifugation. Luciferin substrate was then added and luminescence was 
detected. The highest level of luminescence was seen in cells transfected with 
polymersomes collected following the slowest centrifugation (fig. 3.6 A). The amount 
of luminescence detected then decreased as the centrifuge speed used to collect 
the polymersomes increased. Moreover when luminescence was plotted against the 
amount of encapsulated DNA measured in each sample of polymersomes used 
there is a linear relationship between the amounts of encapsulated DNA and the 
level of transfection seen (fig. 3.6 B).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Luciferase transfection with different polymersome fractions. Polymersomes 
collected following each centrifugation were used to transfect HEK293T cells. The cells were 
incubated with the 0.5mg of various polymersome fractions for 48 hours before luciferin substrate 
was added and luminescence was detected (A). Luminesce detected was plotted as a function of 
the amount of encapsulated DNA in each fraction used (B). n=3. * p<0.05 One-way ANOVA with 
Turkey’s multiple comparison post-hoc test. 
A B 
* 
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3.2.2.2 Using Polymersomes to Overexpress SMN 
Following successful transfection of HEK cells with luciferase reporter plasmid we 
further investigated whether polymersomes could be used to deliver SMN gene 
therapy for SMA. We therefore prepared polymersomes encapsulating plasmid DNA 
encoding the human SMN gene. The polymersomes were then centrifuged at an r.c.f 
of 10000 x g to collect the majority of DNA containing polymersomes and exclude 
empty polymersomes. The pelleted polymersomes were used to transfect HEK293T 
cells. After incubating the cells for 48 hours the cells were harvested for protein 
and mRNA for Western blot and QPCR analysis respectively. Cells were also 
transfected with SMN plasmid DNA alone using calcium phosphate as a positive 
control. Western blot was performed on protein samples (fig. 3.7 A) and 
densitometric analysis revealed a 2.6-fold increase in SMN protein levels following 
transfection with polymersomes compared to untransfected controls (fig. 3.7 B, n=3, 
p<0.05, t-test). For comparison calcium phosphate transfection resulted in a 7.8-fold 
increase in SMN protein expression. Real-time QPCR was performed on mRNA 
extracted from transfected HEK293T cells and revealed a 38-fold increase in SMN 
mRNA following transfection with SMN plasmid DNA-loaded polymersomes (fig. 3.8, 
n=3, p<0.05, t-test). This compares to a 158 fold increase in SMN mRNA following 
transfection using calcium phosphate.   
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Figure 3.7 Polymersome-mediated SMN transduction in HEK293T cells. HEK293T cells 
were incubated with polymersomes encapsulating SMN plasmid DNA for 48 hours and protein 
levels were assessed by Western blot (A). Densitometric analysis (B) revealed SMN levels were 
increased by an average of 2.1-fold following transfection with polymersomes compared to 
untransfected cells. n=3. * p<0.05 t-test versus untransfected. 
Figure 3.8 Increased levels of SMN mRNA following transfection by polymersomes. 
HEK293T cells were incubated with polymersomes loaded with SMN plasmid DNA. 48 hours 
post transfection mRNA levels were measured using QPCR. Data represents ddCt values 
relative to GAPDH and normalised to untransfected cells. Transfection with polymersomes 
increased SMN mRNA levels by 35.8 fold compared to untransfected. n=3. * p<0.05 t-test 
versus untransfected with Mann-Whitney post-hoc test. 
A B 
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3.2.2.3 Overexpression of SMN in an In Vitro Model of SMA 
We used a fibroblast cell line derived from a SMA type 1 child to establish a proof-
of-concept for SMN replacement using polymersomes Polymersomes encapsulating 
SMN plasmid DNA were incubated with the cells for 72 hours before mRNA was 
extracted. QPCR revealed a 367-fold increase in SMN mRNA when normalised to 
GAPDH mRNA expression following treatment with polymersomes (fig. 3.9, n=3, 
p<0.05, t-test). Again transfection using calcium phosphate was used for comparison 
which led to an increase in SMN mRNA expression of 2378-fold (fig. 3.9). 
Figure 3.9 Polymersome-mediated SMN gene replacement in type I SMA fibroblasts. 
SMN-deficient fibroblasts were transfected with polymersomes loaded with SMN plasmid DNA. 
72 hours later mRNA was extracted, RT-PCR was performed and the resulting cDNA was used 
for QPCR. Analysis revealed an increase in SMN mRNA of over 600-fold compared to 
untransfected cells. n=3 * p<0.05 t-test versus untransfected with Mann-Whitney post-hoc test. 
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SMA fibroblasts isolated from a type 1 SMA child have low levels of SMA and 
therefore do not display the characteristic SMN gems that are seen in wild-type 
cells. Immunofluorescence was used to investigate whether transfection using 
polymersomes could restore protein levels by observing the presence of SMN. 
Furthermore immunofluorescence enabled us to analyse the transfection efficiency 
of polymersomes in vitro. Cells were incubated with polymersomes encapsulating 
SMN plasmid DNA for 72 hours before being fixed and stained using mouse 
antibody against SMN. Cells transfected with SMN plasmid using calcium phosphate 
were used as a positive control in this study.  
Microscopy analysis revealed an increase in SMN fluorescence in cells transfected 
using polymersomes as well as in cells transfected using calcium phosphate. 
Following transfection with calcium phosphate quite a low percentage of cells were 
transfected (approximately 10%), however, cells that were transfected displayed a 
very high level of SMN fluorescence (fig. 3.10). Cells transfected by calcium 
phosphate displayed SMN gems throughout the cytoplasm as well as in the nucleus, 
this has previously been reported following lentiviral-mediated overexpression of SMN 
(Azzouz et al., 2004). It is expected that the presence of SMN gems in the 
cytoplasm is due to unusually high levels of SMN protein being expressed. 
Interestingly following transfection using polymersomes a higher percentage of cells 
appeared to be transfected (fig. 3.10). Although the SMN was not as highly 
expressed as with calcium phosphate cells transfected with polymersomes did 
display restored SMN gems in the nucleus. This demonstrates that polymersomes 
can be used to transfect cells and cause restoration of functional protein in an in 
vitro model of SMA. 
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Figure 3.10 Polymersome-mediated SMN replacement in type I SMA patient fibroblasts. SMN 
deficient fibroblasts were incubated with polymersomes loaded with SMN plasmid DNA for 72 hours 
before being fixed and stained for SMN. Following polymersome-mediated transduction cells 
displayed increased fluorescence. Scale = 20µm. n>100 cells analysed for SMN fluorescence per 
group. 
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3.3 Discussion 
Polymersomes composed of PMPC-PDPA have been shown to enter many cell types 
with very low levels of toxicity (Massignani et al., 2009). We have used a rhodamine-
labelled PMPC25-PDPA70 polymersomes to confirm uptake in a human cell line 
(HEK293T cells). These cells display a decrease in viability following incubation for 
48 hours with high polymersome concentrations, however the concentration used for 
further in vitro experiments (0.5mg/ml) only caused a small reduction in cell viability 
as assessed by MTT assay. Fluorescent microscopy revealed that incubation with 
this concentration of polymersomes for 48 hours led to uptake in almost all cells, 
with the majority of fluorescence localising in the cytoplasm. The even distribution 
of fluorescence throughout the cytoplasm suggests that these pH sensitive 
polymersomes break up in the acidic environment of the endosome following 
endocytosis and the polymer becomes dispersed throughout the cell, as previously 
reported (Massignani et al., 2009).  
Polymersomes have previously been used to deliver nucleic acids including DNA to 
cells leading to transfection. To investigate the possibility of using polymersomes as 
a delivery vehicle for gene therapy to treat SMA we first wanted to improve the 
encapsulation efficiency, or find a way of sorting polymersomes to remove those 
that have not encapsulated any DNA. Theoretically the size and shape of structures 
formed from amphiphilic block-copolymers in an aqueous environment can be 
controlled by changing the size of each block. However there is a wide distribution 
of particle sizes within the solution of polymersomes produced with PMPC25-PDPA70, 
including micelles of <40nm, and vesicles of >400nm. We hypothesized that we 
could increase the percentage of polymersomes that contained DNA by removing 
polymersomes that were unlikely to have encapsulated DNA due to their small size, 
and thus in effect enhance encapsulation efficiency.  
To investigate how centrifugation could affect the amount of encapsulated DNA in 
the polymersome formulation, polymersomes encapsulating luciferase plasmid DNA 
were centrifuged at an r.c.f of either 5000, 10000 or 20000 x g. When the amount 
of encapsulated DNA was calculated, normalised to polymer concentration for each 
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sample there was a trend towards higher DNA concentration at lower centrifuge 
speeds. 
To check how well particle size could be separated by centrifugation at different 
speeds polymersomes were produced encapsulating luciferase plasmid DNA and 
centrifuged at increasing speeds. The particle size of polymersome collected after 
each centrifugation was measured which revealed that the slower rounds of 
centrifugation removed many of the largest particles. There was a clear shift 
towards smaller sized particles collected after faster centrifugations. However the 
size distribution curves for the different polymersome fractions overlapped which 
demonstrates that the method of sorting particle size by centrifugation is not totally 
effective. The pelleting of polymersomes by centrifugation also enables the 
concentration of the polymersome solution to be controlled by varying the volume 
that the pellet is re-suspended in. Furthermore pelleting polymersomes and removing 
the supernatant led to exclusion of unencapsulated DNA. 
It may be possible to separate different sized particles by other methods such as 
by gel permeation chromatography or using a hollow fibre filtration system. Gel 
permeation chromatography was initially tested to purify polymersomes using a 
column of sepharose by size however this was inefficient and difficult to accurately 
control. Furthermore this method of gel permeation chromatography was unable to 
separate free plasmid DNA from polymersomes due to their similar size. Hollow fibre 
filtration systems are useful for excluding particles below a certain size from a 
solution however it may be difficult to use this method to generate a series of 
particle fractions of different size. Centrifuge columns could also be used to more 
accurately separate different sized particles using centrifugation, however due to 
time constraints this possibility was not explored.   
The different polymersome fractions collected following centrifugation at increasing 
speeds were then analysed to measure the amount of encapsulated DNA in the 
polymersomes collected after each centrifugation. Remarkably there was a large 
difference between the concentrations of DNA encapsulated in the polymersomes 
collected after different centrifugations. The amount of DNA encapsulated in 
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polymersomes collected following the first centrifugation was higher than in any 
other fraction collected thereafter. The amount of encapsulated DNA then decreased 
in polymersomes collected following each round of centrifugation. When plotted 
against the average particle diameter for each solution it was observed that as 
average particle diameter increases so does the amount of encapsulated DNA.  
To check that the improvement in encapsulation efficiency through selection of the 
largest particles can translate to improvement in transduction efficiency we then 
used these polymersomes to transfect HEK293T cells. Assessing the luciferase 
activity 48 hours post-transduction revealed that the polymersomes collected after 
the first centrifugation at the slowest speed did indeed generate the highest level of 
luminescence. Furthermore when the luminescence detected was plotted against the 
amount of DNA encapsulated in the polymersomes used for each transfection there 
was a linear relationship between the amount of encapsulated DNA and the level of 
luminescence detected.  
We show here that by removing empty polymersomes transfection efficiency can be 
improved. Another benefit of this approach is improving reliability of the transfection. 
Without purifying polymersomes the solution contains polymersomes that have 
encapsulated little or no DNA as well as polymersomes that contain a high 
concentration of DNA. Using a small sample of this solution for transfections is 
likely to cause a large variation in the amount of transfection seen between, or 
even within experiments.  
Following successful transfections with a luciferase reporter plasmid we investigated 
how well polymersome transfection could lead to SMN gene transfer. Western blot 
analysis revealed a 2.6 fold increase in SMN protein expression following 
transfection by polymersomes encapsulating SMN plasmid DNA. Furthermore QPCR 
analysis revealed an increase in SMN mRNA of 38  fold.  Since HEK293T cells are 
an embryonic cell line they express a high level of SMN protein, therefore an 
increase in expression by over 2 fold could be considered a significant outcome. 
The overexpression following transfection by polymersomes was not as high as seen 
for calcium phosphate however a direct comparison between the two methods 
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cannot be made. Calcium phosphate is known to be toxic to cells therefore the cell 
growth media is removed after 6 hours and replaced with fresh media. If calcium 
phosphate had been incubated with the cells for as long as the polymersomes we 
would expect to see a large amount of cell death. Furthermore the amount of DNA 
used for calcium phosphate transfection differs from the amount encapsulated in 
the polymersomes used.    
To further investigate the possibility of using polymesomes to deliver gene therapy 
for SMA we tested the ability of polymersomes to overexpress SMN in an in vitro 
model of SMA. A fibroblast cell line derived from a type 1 SMA patient was used 
which displays low levels of SMN. We first transfected these cells with polymersomes 
containing plasmid DNA expressing the human SMN1 gene and assessed the mRNA 
levels by QPCR. This revealed an increase in SMN mRNA of over 300 fold. 
Immunofluorescence of SMN-deficient fibroblasts transfected with polymersomes 
encapsulating SMN plasmid DNA revealed an increase in SMN protein levels.  
The work here shows that polymersomes can be used to encapsulate plasmid DNA 
to cause transfection as reported previously (Lomas et al., 2007). Furthermore the 
data here shows that polymersomes encapsulate DNA in a size dependent manner. 
Increase of SMN mRNA and protein levels in an in vivo model of SMA demonstrates 
that polymersomes could potentially be used as a non-viral gene therapy vector for 
SMA. As mentioned in the introduction to this section polymersomes are a new 
technology that needed optimisation of production, encapsulation and transfection 
before using the methods detailed in this section. Therefore the time spent on 
optimisation meant it was not possible to go on to test this non-viral vector system 
in vivo. It would be interesting to follow-up this research by testing the transfection 
efficiency of polymersomes in vivo and ultimately delivering SMN plasmid DNA to an 
in vivo model of SMA. 
 
 
  
87 
 
 
  
88 
 
Chapter 4  
 
AAV5-mediated Transduction in the CNS 
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4.1 Introduction 
To achieve effective gene therapy for disorders of the central nervous system (CNS) 
it is important to develop vector systems capable of widespread gene transfer in 
the brain and spinal cord. To do this a gene delivery vector must be able to pass 
the blood-brain barrier (BBB) and enter the CNS. Different AAV serotypes have been 
shown to have different tropisms for tissues leading to different transduction profiles 
(Zincarelli et al., 2008).  We decided to investigate whether AAV5 could enter the 
CNS following intravenous injection of neonatal mice. 
AAV5 genome sequencing revealed some similarity to AAV2 with a level of sequence 
consensus of around 50% (Bantel-Schaal et al., 1999; Chiorini et al., 1999). However 
sequencing demonstrated that AAV5 is a distinct serotype with a high degree of 
heterogeneity seen in the region encoding capsid proteins. Analysis of RNA 
generated following viral infection of AAV5 also revealed significant differences in 
transcription profiles compared to AAV2 (Qiu et al., 2002).  
AAV5 can transduce both neurons and astrocytes following direct injection of this 
vector system to the CNS (Davidson et al., 2000). Interestingly following direct 
injection to the striatum AAV5 caused extensive spread of transduction through 
much of the injected hemisphere. In comparison AAV2 and AAV4 mediated a more 
localized pattern of transduction and a much lower level of transgene expression 
(Davidson et al., 2000). However when delivered to the right lateral ventricle 
transduction by this vector system was predominantly localized to the ependyma. 
Furthermore AAV5-mediated transduction increased between 3 and 12 weeks, 
whereas AAV4 transduction remained constant and AAV2 transduction was lost by 
12 weeks. Self-complementary AAV5 (scAAV5) has also been injected directly into 
the retina of a mouse model of a severe form of retinal dystrophy (Leber’s 
congenital amaurosis-2). Remarkably scAAV5-mediated expression of the target gene 
restored visually evoked behaviour to photoreceptors and prevented degeneration of 
cone cells (Pang et al., 2010).  
90 
 
Systemic delivery of various AAV serotypes has previously been performed to assess 
transduction levels in adult mice (Zincarelli et al., 2008). Bioluminescence analysis 
following intravenous (IV) administration of various AAV serotypes to adult mice 
revealed AAV5 caused lower overall expression than AAV1, 6, 8, 7 and 9. Tissue 
analysis showed that transgene expression was mainly confined to the liver following 
AAV5 administration. Viral genome copy number however revealed >104 copies/µg of 
genomic DNA in the brain, kidney and lung at 100 days post injection. Recently the 
efficiency of different AAV serotypes to transduce the CNS following IV injection of 
neonates has been assessed using the CAG promoter with tissue taken at 21 days 
(Zhang et al., 2011). At 21 days AAV5 and AAV2 were found to generate much 
lower levels of transgene expression than other vectors. Image analysis revealed 
that AAV5 caused low transgene expression the brain and spinal cord. However 
analysis of the efficiency of AAV5 to transduce motor neurons was not reported. 
Intraperitoneal (IP) injection of AAV5 has also been investigated in neonates (Ogura 
et al., 2006). Overall transgene expression was higher following IP injection than IV 
injection. Transgene expression was high and long lasting however it was confined 
to the peritoneum, therefore IP injection would not be sufficient to treat CNS 
disorders such as SMA.   
Comparison of the transduction efficiency of different AAV serotypes in the brain of 
young adult rats has previously been performed (Blits et al., 2010). The red nucleus 
of the rat brain has projections through the spinal cord and was injected directly 
with different AAV serotypes.  At one week post injection AAV5 transduced fewer 
neurons than AAV6 however the number of neurons transduced by AAV5 increased 
over time whilst the number of AAV6 neurons remained constant. Interestingly as 
with intrastriatal injection (Davidson et al., 2000) AAV5 transduction spread to 
neurons outside the red nucleus, unlike other AAV serotypes (Blits et al., 2010).  
Direct injection of different AAV serotypes into the dorsal root ganglia was 
performed to assess how efficiently these sensory neurons were transduced (Mason 
et al., 2010). The highest level of transduction was obtained with AAV5, followed by 
AAV6 and AAV1. The percentage of cells transduced by AAV5 increased over time 
91 
 
from 1 week to 12 weeks. At 12 weeks transduction was also seen in fibres of the 
sciatic nerve and axons in the dorsal roots and entering the spinal cord.  
The aim of this section is to undertake a small pilot study to assess the efficiency 
of AAV5 transduction in the CNS following intravenous injection in neonate mice. 
Furthermore the ability of two different promoters to drive transgene expression in 
the CNS will be analysed. The two promoters used in this study are the 
cytomegalovirus (CMV) promoter and the CAG promoter which is a combination of 
the CMV early enhancer element and the chicken β-actin promoter. Both of these 
promoters have been used previously to drive transgene expression in the CNS 
(Gray et al., 2011; Zhang et al., 2011). CNS tissue was extracted at 4 and 8 weeks 
following intravenous injection of the vectors at post-natal day 1 in order to assess 
whether transgene expression changed over time. 
 
4.2 Results 
 
4.2.1 AAV5-mediated GFP Transduction in the Brain 
 
4.2.1.1 Transduction of Neurons and Astrocytes in the Brain 
We compared two AAV5 viral vectors expressing green fluorescent protein (GFP) or 
humanised recombinant GFP (hrGFP) under the control of a CAG or a CMV promoter 
respectively. Wild-type mice were intravenously injected with 10µl (3.3x1010 vector 
genomes (vg)) of AAV5-CAG-GFP (n=6) or 10µl (1.23x1011 vg) of AAV5-CMV-hrGFP 
(n=6) at postnatal day one. Note that two slightly different amounts of vector 
genomes were injected due to different vector concentrations. The vectors were not 
diluted to matching concentrations as we wanted to deliver as much vector as 
possible for each group and did not expect this small difference in concentration to 
affect transduction. 
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GFP expression in the brain and spinal cord was assessed by performing 
immunohistochemistry on brain and spinal cord sections at 4 weeks (n=3) or 8 
weeks (n=3) post vector administration. In the AAV5-CAG-GFP treatment group a 
modest amount of transduction of both neurons and astrocytes or glial cells was 
seen throughout the brain (fig. 4.1).  Fig. 4.1 shows that GFP-positive neurons 
display co-localisation with staining against NeuN (fig. 4.1 D&E) and astrocytes 
display co-localisation with GFAP positive cells (fig. 4.1 B). Moreover many GFP-
positive fibres were seen that appeared to be axons, without any visible cell body 
transduced (fig 4.1 C). Almost no transduction was detected in the AAV5-CMV-hrGFP 
treatment group therefore the following sections will only summarise the data 
obtained with AAV5-CAG-GFP.  
 
4.2.1.2 Quantification of Transduced Astrocytes and Neurons in the Brain  
The number of transduced astrocytes and neurons in brain sections was determined 
following injection of AAV5-CAG-GFP. The amount of transduced cells per section 
was counted per animal and the cell type (either neuronal or glial) was determined 
by the morphology of the transduced cell. When grouped together the results 
suggest that there is a higher level of transduction after 8 weeks than after 4 
weeks (fig. 4.2 A) although this is not significant (two-way ANOVA).  Looking at the 
individual data (fig. 4.2 B) it is obvious that these results are skewed by one animal 
which is transduced more than any other. Furthermore there was one animal in the 
8 weeks group with no transduction detected and one animal in the 4 weeks group 
with only one transduced cell observed. It is clear that there is variability in the 
levels of transduction observed in different animals. Among the 6 animals in the 
CAG promoter group there were one animal with a moderate level of GFP 
expression, 3 animals low transgene expression and two animals with almost no GFP 
expression (fig. 4.2 B).   
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Figure 4.1 AAV5-mediated GFP expression in the brain. Wild-type mice were injected at postnatal 
day 1 with AAV5-CAG-GFP, brains were extracted at 4 or 8 weeks post-injection, sectioned and 
stained for DAPI (blue), GFP (green), GFAP (red; A, B & C) or NeuN (red; D & E). A: transduced 
astrocytes and a neuron at 8 weeks in the cerebral cortex (scale = 200µm), B: transduced astrocyte in 
the cortex at 4 weeks (scale = 20µm). C: transduced fibres in the cortex which appear to be axons at 
8 weeks (scale = 50µm). D & E: transduced neurons within the striatum which co-localise with NeuN 
staining at 8 weeks. D: Scale = 50µm. E: Scale = 20µm 
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 Mouse ID Astrocytes per section Neurons per section 
4 weeks 209 0.94 0.75 
 208 0.076 0 
 508 0.43 0.36 
8 weeks 210 0.57 0.71 
 227 0 0 
 228 12.5 9.7 
 
 
 
 
Unfortunately the high variability and poor transduction efficiency in this pilot study 
means it is challenging to compare the two time points. However the presence of 
one animal with a relatively good level of transduction at 8 weeks demonstrates 
that the transduction with AAV5-CAG-GFP can be long lasting. The table (fig. 4.2 B) 
shows that there was little difference between the number of astrocytes and the 
number of neurons transduced for each mouse.  
 
A 
B 
Figure 4.2 Quantification of astrocytes and neurons transduced in the brain. A: 
number of GFP-positive astrocytes and neurons per brain section at 4 or 8 weeks post-
injection of AAV5-GFP (n=6). Data shows mean ± SEM from between 13 and 16 sections 
per animal. No significant difference between cell types transduced or between 4 weeks and 
8 weeks (two-way ANOVA). B: average number of astrocytes and neurons transduced per 
brain section for each mouse. 
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4.2.1.3 Transduction of the Cerebellum 
As mentioned above there were many fibres that appeared to be axons that were 
transduced, without any visibly transduced cell body (fig. 4.1 C). Some transduction 
of tracts within the cerebellum was also identified (fig. 4.3). This transduction was 
mainly confined to distinct bundles in the white matter and was found throughout 
the cerebellum.  
Figure 4.3 Transduction in the cerebellum. Staining of brain sections for GFP (green), NeuN 
(red) and DAPI (blue) revealed transduction of fibres in the cerebellum. A: low magnification image 
of the cerebellum with arrows highlighting transduced fibres, scale = 200µm. B: higher 
magnification image of (A), scale = 20µm. Images from tissue taken at 8 weeks.  
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4.2.1.4 Transduction within the Ventricles 
By far the highest area of transduction seen in the brain was within the ventricles, 
which is most likely to be the choroid plexus (fig. 4.4 A & B). The choroid plexus is 
involved in the production of cerebrospinal fluid (CSF) and therefore does not 
contain such a tightly regulated BBB as the rest of the brain. This would explain 
why this area would be more easily transduced following intravenous injection of 
AAV5. Interestingly it was observed that areas of the brain surrounding the 
ventricles were also transduced where high levels of transduction in the ventricles 
were seen (fig. 4.4 A). This may suggest a route of entry for AAV to transduce the 
brain. Furthermore transduction of the pineal gland was seen in one animal, which 
is also outside of the BBB (fig. 4.5 A). The transduction of surrounding axons and 
astrocytes also suggests that viral vectors may have been able to take advantage 
of the lack of BBB in this area. The level of transduction found in the ventricles 
correlated with the level of transduction in the rest of the brain; the animal with 
the highest level of astrocytes and neurons transduced also had the highest level 
of ventricular transduction. This suggests that the animals with a lower level of 
transduction received a lower load of viral vectors. It could be argued that the 
choroid plexus is outside the blood brain barrier and therefore the high level of 
transduction seen here suggests that the AAV5 vector does not easily pass the 
BBB.   
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Figure 4.4 Transduction within the 3rd ventricle. Staining of brain sections for DAPI (blue), GFP 
(green) and NeuN (red) revealed a high amount of transduction within the 3rd ventricle. A: 
transduction of the choroid plexus (bottom left arrow) within the third ventricle and transduction of the 
periventricular region (top arrow and right arrow). Scale = 200µm. B: high magnification image of 
transduction of the choroid plexus. Scale = 20µm. Images from tissue taken at 8 weeks. 
Figure 4.5 Transduction of the pineal gland and surrounding area. A brain sectioned 8 weeks 
post-injection of AAV5-GFP and stained for DAPI (blue), GFP (green) and NeuN (red) revealed GFP 
transgene expression in the pineal gland (arrow). A high level of transduction of cells and axons in 
the surrounding area was also seen. Scale = 200µm. Image from tissue taken at 8 weeks. 
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4.2.2 AAV5-mediated Transduction in the Spinal Cord 
 
4.2.2.1 Transduction of Spinal Cord Neurons 
The main interest of this chapter is to investigate whether AAV5 is a suitable vector 
system to treat SMA. To successfully treat SMA with gene therapy the vector must 
be able to transduce motor neurons in the lumbar spinal cord. Spinal cords were 
collected from mice at 4 and 8 weeks following IV injection of AAV5-GFP and 20µm 
sections were stained with anti-GFP alongside a neuronal marker (NeuN) (fig. 4.6). 
Very few transduced neurons were observed in the spinal cord which appeared to 
be less transduced than the brain (fig, 4.6). Furthermore only a small number of 
transduced neurons were found in the ventral horn region with the morphology of 
motor neurons (fig. 4.6 C). Therefore AAV5 did not readily transduce neurons in the 
lumbar spinal cord. Interestingly many GFP-positive fibres were observed in the 
spinal cord (fig. 4.6 D). These transduced fibres appeared to be axons and were 
similar to those found to be transduced in the brain (fig. 4.1 C).  
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Figure 4.6 Neuronal transduction in the lumbar spinal cord. 4 or 8 weeks following IV injection of 
AAV5-GFP spinal cords were extracted, sectioned and stained for DAPI (blue), GFP (green) and 
NeuN (red). A: transduced neurons and transduction in the ventral column at 4 week. Scale = 100µm. 
B: transduced neuron and axons at 8 weeks. Scale = 200µm. C: high magnification image of a 
transduced neuron at 8 weeks. D: high magnification image of transduced axons seen in (B). Scale = 
50µm 
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4.2.2.2 Transduction of Astrocytes in the Spinal Cord 
Further to investigating levels neuronal transduction in the spinal cord following 
intravenous injection of AAV5 spinal cords were also analysed for the presence of 
transduced astrocytes. Spinal cord sections were stained with GFP and GFAP to 
identify transduced astrocytes. Only a small number of cells were found to express 
GFP which co-localised with GFAP staining (fig. 4.7). This shows that AAV5 is able to 
transduce some astrocytes in the spinal cord but with low efficiency. 
 
 
 
 
 
 
 
Figure 4.7 AAV5-mediated transduction of astrocytes in the spinal cord. Spinal cords of mice 
were extracted from mice 4 weeks and 8 weeks after vector delivery and were sectioned and 
stained for DAPI (blue) GFP (green) and GFAP (red). This revealed a small number of transduced 
astrocytes in the spinal cord. Scale = 50µm. Images from tissue extracted at 8 weeks. 
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4.2.2.3 Quantification of Transduction in the Spinal Cord 
To assess the level of transduction within the spinal cord following intravenous 
injection of AAV5-GFP the number of GFP-positive astrocytes and neurons was 
counted (fig. 4.8). As with the brain the variation between animals coupled with the 
low level of transduction meant that it was difficult to ascertain any strong 
conclusions from this quantification. Overall there were more GFP-positive neurons 
than astrocytes within the spinal cord, however this is not statistically significant (t-
test) and only two of the five spinal cords sectioned displayed any transduced 
astrocytes and neurons. As mentioned above there was a high number of GFP-
positive axons seen within the spinal cord (fig. 4.6 D). Interestingly transduced axons 
were observed in many of the spinal cord sections that displayed no GFP-positive 
neurons or astrocytes. The percentage of sections containing GFP-positive axons 
was calculated revealing that approximately 30% of spinal cord sections displayed 
some transduction of axons in tissue taken at 8 weeks (n=3, data not shown). 
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 Mouse ID Astrocytes  
per section 
Neurons  
per section 
4 weeks 209 0.1 0.8 
 208 0 0 
8 weeks 210 0 0 
 227 0 0 
 228 0.19 0.35 
 
 
 
 
 
 
  
 
 
 
A 
B 
Figure 4.8 Quantification of neurons and astrocytes transduced in the spinal cord. Spinal cord 
sections were assessed for the presence of GFP-positive astrocytes and neurons. A: average 
number of GFP-positive astrocytes and neurons per spinal cord section extracted at 8 weeks post 
injection. Data shows mean ± SEM, from between 10 and 30 sections per animal, n=3. No significant 
difference between cell types (t-test).  B: average number of astrocytes and neurons transduced for 
each mouse.  
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4.2.2.3 Transduction of Dorsal Root and White Matter 
Spinal cords extracted following AAV5-GFP administration were sectioned and 
stained to analyse GFP expression. Some spinal cord sections contained the dorsal 
root alongside the spinal cord. The dorsal root connects the spinal cord to the 
dorsal root ganglion which contains sensory neurons that innervate the muscles of 
the lower limb. The dorsal root areas were found to be highly transduced (fig. 4.9 
A&B). It is therefore likely that this area is transduced via retrograde transport of 
viral vectors from the muscle. Transduction through retrograde transport would 
explain why this area is more highly transduced than the rest of the spinal cord as 
this route avoids crossing the BBB. Furthermore sections close to the dorsal root 
displayed high levels of transduction of cells and fibres (fig. 4.9 B). Transduction of 
cells in areas of the spinal cord near the dorsal root suggests transduction in the 
spinal cord may be mediated through retrograde transport rather than through the 
BBB. Consistent with previous reports investigating the transduction profile of AAV5 
in adult mice (Zincarelli et al., 2008), no transduction was seen within the 
gastrocnemius muscle (data not shown). The white matter areas of the spinal cord 
also displayed high levels of transduction (fig. 4.9 C). The high levels of 
transduction found in the dorsal root coupled with the transduction seen in the 
white matter and fibres in the spinal cord suggest a tropism of AAV5 for white 
matter areas rather than for astrocytes or neurons.  
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Figure 4.9 AAV5-mediated transduction in spinal cord white matter. Spinal cords were sectioned 
and stained for DAPI (blue), GFP (green) and NeuN (red). A: GFP transgene expression in the dorsal 
root and of nearby tissue. Scale = 100µm. B: higher magnification image of (A) (scale = 50µm), 
highlighting transduction in the dorsal root and nearby tissue. C: transduction in the ventral column. 
Scale = 100µm. Images from tissue extracted at 8 weeks. 
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4.3 Discussion 
To ascertain whether AAV serotype 5 would be a good candidate for a gene 
therapy vector to treat CNS disorders, in particular SMA, we injected neonatal wild-
type mice with 10µl AAV5 expressing GFP. This equates to 1.23x1011vector genomes 
for AAV5-CMV-GFP, and 3.3x1010 vector genomes for AAV5-CAG-GFP. Two different 
GFP vectors were used under the control of different promoters (CMV and CAG), 
and CNS tissue was extracted at two different time points to assess the level of 
transduction by immunofluorescence. The aim was to compare which promoter 
provided the highest level of GFP expression in vivo and whether transduction was 
highest at 4 weeks or 8 weeks post-injection. 
The brains and spinal cords of injected mice were sectioned and stained using an 
antibody against GFP alongside other antibodies against neuronal and glial markers 
(NeuN and GFAP respectively). Analysis of the immunofluorescence in the brain 
revealed a modest level of transduction with AAV5-CAG-GFP, with transduced cells 
appearing to be spread randomly throughout the brain. There was a similar amount 
of astrocytes and neurons transduced in the brain, with fine fibres also transduced 
that were assumed to be axons. Some of the transduced fibres resembled 
oligodendrocytes, however it was not possible to confirm the cell type from the 
staining performed. It would have possible to confirm this by co-immunolabelling 
with an oligodendrocyte marker such as an anti-CNPase antibody. A distinct pattern 
of transduction of bundles within the cerebellum was also observed. The highest 
level of transduction in the brain was seen in structures within the ventricles. The 
transduced cells within the ventricles make up the choroid plexus and 
circumventricular organs.  
In the spinal cord a low number of astrocytes and neurons were found to be 
transduced by AAV5-CAG-GFP, with very few motor neurons expressing GFP. However 
there was a high amount of GFP positive fibres observed which appear to be axons. 
Furthermore transduction was also seen in white matter areas of the lumbar spinal 
cord such as the ventral and dorsal column. Some spinal cord sections also 
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contained parts of the dorsal root which displayed a much higher level of 
transduction than in the spinal cord. 
As mentioned above we aimed to compare the difference in expression between two 
different promoters, CMV and CAG. Almost no transduction was seen in brains and 
spinal cords of mice injected with AAV5-CMV-GFP, therefore only the transduction in 
animals injected with AAV5-CAG was quantified. It is not clear why the vector with 
the CMV promoter transduced so few cells since this promoter is used routinely to 
drive expression of genes in viral vectors. It must be noted that the two viral 
vectors used do not express exactly the same gene; the vector using CAG 
expresses wild-type GFP whereas the vector using CMV expresses humanised renilla 
GFP (hrGFP) however this should not negatively affect expression.  
The level of transduction seen in the CNS of animals injected with AAV5-CAG-GFP 
varied widely between animals. It was therefore difficult to assess how expression 
may change between 4 and 8 weeks.  The highest level of transduction was seen 
from an animal in the 8 weeks post-injection group. However the variability within 
the group means we cannot say for certain that transduction increases over time; 
however it shows that transduction can be maintained for up to 8 weeks. The 
variation seen within the CAG group may be due to a technical issue regarding the 
variability of injecting neonatal animals. It may also be natural variation in the 
amount of viral vectors that was able to enter the brain and spinal cord. One way 
to test this would be to assess the level of transduction in an organ that is highly 
transduced such as the liver. If there was also a large variation in transduction 
levels in the liver then the variation is likely to be due to human error. If a similar 
level of transduction was seen in the livers of all animals then the variation seen in 
the CNS is likely to have resulted from natural variation between animals.  
The data presented here is generally in agreement with previously published results 
from a study that investigated the transduction efficiency of AAV5 following 
intravenous injection in neonatal mice (Zhang et al., 2011). AAV5 was reported to 
generate low levels of transduction in the brain, which has also been shown here. 
Interestingly the pattern of transduction of the choroid plexus within the ventricles 
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of the brain shown here has been also reported for other AAV serotypes (Zhang et 
al., 2011). Furthermore Zhang et al., demonstrated that transduction of the spinal 
cord by AAV5 was low, however did not report whether AAV5 could specifically 
transduce motor neurons. The data here adds to this by showing that this vector 
system does not efficiently transduce neurons in the lumbar spinal cord.  
AAV5-mediated transduction has previously been investigated in CNS tissue 
extracted at 21 days (Zhang et al., 2011). Here later time points of 4 weeks and 8 
weeks have been used. Studies have shown that AAV5-mediated transgene 
expression increases over time and that AAV5 can cause transgene expression for 
up to 200 days post-injection (Zincarelli et al., 2008; Mason et al., 2010). However it 
is difficult to conclude from the data here whether transgene expression in the CNS 
increases between 4 and 8 weeks. The observations made here that AAV5-mediated 
transduction appears to spread from transduced dorsal root to cells in the spinal 
cord supports previously published data showing that direct injection of the dorsal 
root ganglia can cause some transduction in the spinal cord (Mason et al., 2010).  
The low level of transduction in the brain and spinal cord following systemic 
delivery of AAV5 suggests that this serotype cannot easily pass the blood brain 
barrier. This is compounded by the fact that areas outside of the BBB such as 
circumventricular organs and the choroid plexus in the brain and the dorsal root in 
the spinal cord express high levels of GFP. Furthermore it was observed that areas 
of the brain and spinal cord close to highly transduced areas such as the dorsal 
root and choroid plexus displayed higher levels of transduction. It can therefore be 
postulated that AAV5 viral vectors may enter the brain through the CSF and enter 
the spinal cord through retrograde transport. Interestingly there appeared to be 
tropism of AAV5 for white matter in the CNS demonstrated by transduction of 
bundles in the cerebellum, and transduction in the ventral and dorsal column and 
the dorsal root. Furthermore the presence of GFP positive fibres was seen 
throughout the brain and spinal cord more often than transduced cell bodies. These 
fibres appear to be axons suggesting that axons express GFP following AAV5 
transduction more than cell bodies.   
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This small pilot study showed that AAV5 mediated poor gene transfer in the CNS 
following IV delivery in neonate mice. It is possible that some particles may enter 
the CNS through the CSF and by retrograde transport however the low level of 
transduction suggests that AAV5 cannot pass the BBB. Therefore AAV5 is not 
thought to be an appropriate vector for gene therapy to treat SMA. For this reason 
the decision was taken not to expand this study further and increase the number of 
animals used.   
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Chapter 5 
 
AAV6-mediated Expression of hnRNP R 
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5.1 Introduction 
 
hnRNP R was identified in 1998 as a protein of 633 amino acids (Hassfeld et al., 
1998).  This protein contains three adjacent RNA binding domains in the central 
part of the protein as well as an RGG box, another type of RNA binding domain, 
towards the C-terminal. hnRNP R was further identified by a yeast two hybrid screen 
as a binding partner of Smn (Rossoll et al., 2002). However it is not able to bind to 
Smn mutants that reflect mutations seen in SMA suggesting the function of hnRNP 
R is compromised in SMA. Expression of hnRNP R is widespread and is expressed 
most highly during embryogenesis and was shown to be able to bind to RNA, as 
the structural analysis would suggest.  
This protein was observed to co-localise with SMN in the axons of cultured motor 
neurons suggesting it may be involved in the axonal role of SMN. Furthermore 
motor neurons from Smn-/-;SMN2 mice show a reduction of hnRNP R staining in 
distal axons and growth cones (Rossoll et al., 2003). An hnRNP R mutant has also 
been generated that is lacking the ability to bind to SMN, when over expressed in 
differentiated PC12 cells this protein localises more in the nucleus rather than in 
neuritic processes as wild type hnRNP R does (Rossoll et al., 2003). Together this 
suggests that Smn is involved in translocation of hnRNP R to axons.  
Furthermore hnRNP R can bind directly to the 3’UTR of actin and these two 
proteins colocalise in axon terminals of primary mouse motor neurons (Glinka et al., 
2010). However mutant hnRNP R that cannot bind SMN also has a lower affinity for 
actin. This suggests that these three proteins work in conjunction with each other. 
Growth cones of Smn-/-;SMN2 mice have a reduced number of actin mRNA positive 
growth cones and reduced actin staining in these areas, as well as reduced hnRNP 
R staining (Rossoll et al., 2003).   
SMN over-expression in differentiated PC12 cells has been shown to increase axon 
length; the same result was also seen following over-expression of hnRNP R.  
However, over-expression of hnRNP R mutants that lack either SMN binding domains 
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or mRNA binding domains had no effect on axon length (Rossoll et al., 2003). This 
suggests that hnRNP R could be a modifier of SMA axon phenotype through SMN 
and mRNA binding.  Similarly, knockdown of hnRNP R in primary motor neurons 
reduced axon length and calcium channel activity, which replicates SMN knockdown 
(Glinka et al., 2010).  Furthermore this was replicated in zebrafish where injection of 
morpholinos targeted against hnRNP R caused shortening of axons and increased 
axon branching, again replicating the effect of silencing SMN.  
These data suggest that hnRNP R is involved in actin binding through interactions 
with SMA. Interestingly hnRNP R knockdown causes similar effects to SMN 
knockdown and hnRNP R overexpression can compensate for lack of SMN. 
Work by our collaborators has furthered this by showing that hnRNP R is enriched 
in the growth cone of cultured motor neurons of wild-type mice compared to the 
rest of the axon. Conversely in growth cones of axons from Smn-/-;SMN2 mice there 
is 50% less hnRNP. It was also shown that depletion of hnRNP R in purified motor 
neurons reduces actin levels to a similar amount as SMN depletion does.  
Furthermore overexpression of hnRNP R restores actin mRNA levels in Smn-/-;SMN2 
growth cones to almost wild type levels. hnRNP R overexpression was also able to 
rescue the reduction in axon length seen in SMN-/-;SMN2 motor neurons. We 
therefore hypothesized that overexpression of hnRNP R in SMNΔ7 mice would have 
a similar effect to SMN over expression and ameliorate their SMA phenotype. 
Adeno-associated virus serotype 6 was isolated as a contaminant of adenovirus 
stock and is thought to have arisen from a mutation of AAV1 (Rutledge et al., 
1998) or a natural recombination of AAV1 and AAV2 (Xiao et al., 1999) as the 
sequence of AAV6 is very similar to both. AAV2 is the most widely characterised 
serotype of AAVs however there is a large presence of neutralising antibodies 
towards this virus in the human population. It would therefore be advantageous to 
use other serotypes for gene therapy. For example AAV6 can transduce cells in the 
presence of serum from animals exposed to AAV2. AAV6 has previously been shown 
to transduce motor neurons by retrograde transduction (Salegio et al., 2012). It was 
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hypothesized that AAV6 may be able to pass the neonatal blood brain barrier and 
effectively transduce motor neurons after systemic delivery via facial vein injection.    
We therefore decided to use AAV6 to express hnRNP R in neonatal SMNΔ7 mice 
and hypothesized that this would ameliorate the phenotype of these mice. We 
injected 10ul of viral vectors to the facial vein at post-natal day one which is 
considered to be presymptomatic. We injected 7 mice with AAV6-hnRNP R and 
injected 5 mice with AAV6-GFP as controls. To determine the effect of hnRNP R 
expression on disease phenotype the mice were monitored daily for signs of overall 
health and for motor ability, they were then sacrificed when they showed signs of 
severe ill health. Furthermore histological analysis was performed to determine levels 
of transduction in the spinal cord in order to evaluate the efficiency of AAV6 to 
transduce the CNS. 
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Figure 5.1 Body weight assessment. Change in body weight over duration of life span. 
AAV6-hnRNP R n=7, AAV6-GFP n=5. Data points represent mean weight in grams for 
each group with standard error of mean.  Statistical analysis (p>0.05, 2-way ANOVA, 
Bonferroni post-hoc test) revealed no significant difference in weight at any day between 
day 2 and 11. 
5.2 Results 
 
5.2.1 In Vivo Assessment 
 
5.2.1.1 Body Weight 
SMNΔ7 mice, a well-established model of SMA, were used to assess the efficacy of 
AAV6 mediated hnRNP R expression on body weight, functional motor activity, motor 
neuron survival and lifespan of treated animals. AAV6-hnRNP R (n=7) or AAV6-GFP 
(n=5) vectors were injected systemically into the facial vein of postnatal day 1 
SMNΔ7 mice.  
These mice are characterised by progressive muscle weakness and die on average 
2 weeks after birth (El-Khodor et al., 2008).The body weight of all mice was 
monitored daily throughout the study as a measure of overall health. There was no 
significant difference between the weights of AAV6-hnRNP R treated mice and AAV6-
GFP treated mice at any time point (p>0.05 two-way ANOVA) (fig. 5.1).  
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Figure 5.2 Righting reflex assessment. The ability of mice to re-orientate themselves 
after being placed on their back was assessed over the duration of their lifespan. AAV6-
hnRNP R n=7, AAV6-GFP n=5. Data points represent percentage of mice in each group 
that were able to complete the test within 30 seconds.  Statistical analysis revealed 
significant difference overall between the treatment with AAV6-hnRNP R and controls 
(p<0.001) but no significant difference at any individual time point (two-way ANOVA, 
Bonferroni post-hoc test).  
5.2.1.2 Righting-reflex 
To test the general motor ability of these mice we performed a righting reflex test 
daily. This test assessed the success or failure of the mice to reposition themselves 
within 30 seconds after being placed on their back. The functional test revealed 
that overall more AAV6-hnRNP R treated mice were able to successfully complete 
the righting-reflex test when compared to AAV6-GFP mice at all time points (Fig 5.2, 
P<0.001, two-way ANOVA). However righting-reflex monitoring revealed variability 
within groups and between days. Variation between days meant that ability to self-
right on one day was not predictive of being successful the following day. However 
a general trend of reduction in successful mice with time was seen in both groups.  
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Figure 5.3 Survival analysis of SMNΔ7 mice. A: Kaplan-Meier cumulative survival 
curves comparing lifespan of AAV6-hnRNP R injected animals (n=7) and AAV6-GFP 
injected animals (n=5), p<0.01, log-rank (Mantel-Cox) test. B: Comparison of mean 
survival across the two groups (p<0.01, t-test).  
5.2.1.3 Survival 
The first mouse to die in the AAV6-GFP group did so at the age of 3 days whereas 
the first mouse to be sacrificed in the AAV6-hnRNP R group occurred at the age of 
10 days.  This trend continued throughout the study with the median survival of 
AAV6-GFP treated mice being 6 days whilst the median survival of the AAV6-hnRNP 
R group being 14 days. Furthermore the oldest mouse lived for 15 days after 
treatment with AAV6-hnRNP R whereas the longest surviving mouse after treatment 
with AAV6-GFP lived for 12 days (fig. 5.3 A). Mean survival for the AAV6-hnRNP 
treatment group was 13.0±0.76 days compared to 7.20±1.53 days for that of the 
AAV6-GFP treated group (fig. 5.3 B, p<0.01 t-test). Kaplan-Meier analysis revealed 
that treatment of SMNΔ7 mice with AAV6-hnRNP R caused a marginal but significant 
increase in survival compared to treatment with AAV6-GFP (p<0.01, Log-rank (Mantel-
Cox) test).   
 
  
 
  
A B 
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Figure 5.4 Quantification of lumbar spinal cord motor neurons. A: Representative images of 
lumbar spinal cord sections after Nissl staining. Arrows indicate motor neurons. Scale = 20µm. B: 
Quantification of motor neurons in the lumbar spinal cord. Data represents the mean number of 
motor neurons per section for each group. AAV6-hnRNP R n=3, AAV6-GFP n=2. No significant 
difference between AAV6-hnRNP R treatment and AAV6-GFP controls (p>0.05, t-test).  
5.2.2 Histological assessment 
 
5.2.2.1 Motor Neuron Survival 
To assess whether expression of hnRNP R could increase survival of spinal motor 
neurons we labelled and quantified motor neurons of the lumbar spinal cord. 
Lumbar spinal cord was taken from end-stage mice, cut into sections and stained 
for Nissl (cresyl violet).  Motor neurons were identified by their location within the 
anterior horn of the spinal cord as well as their size and morphology. Nissl staining 
highlights RNA in the endoplasmic reticulum and causes dark staining of motor 
neurons. Motor neurons were counted under a light microscope by Dr K. Ning after 
being blinded to treatment groups.  No significant difference was seen between 
groups, although AAV6-hnRNP R treated animals had a slightly higher mean motor 
neuron count than AAV6-GFP injected. 
 
 
 
 
 
 
 
 
A B 
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5.2.2.2 Transduction Efficiency of AAV6 
To assess transduction efficiency of AAV6-GFP transduction in SMNΔ7 mice, lumbar 
spinal cord sections were stained with antibodies against GFP. Sections were then 
analysed using a light microscope to assess levels of transduction in the lumbar 
spinal cord. Staining showed the presence of GFP-positive neurons as well as GFP-
positive astrocytes in the ventral horn of the lumbar spinal cord (fig. 5.5). The top 
and bottom panel (fig 5.5.) show GFP-positive neurons, the cell type was detmined 
by the relative large size of the cell body and presence of protruding axons. The 
transduced cell in middle panel (fig 5.5) is thought to be an astrocyte due to the 
round morphology and presence of small processes. However the total number of 
transduced cells within the spinal cord was very low. To further assess the efficacy 
of AAV6 muscle sections were analysed as AAV6 is known to transduce skeletal 
muscle with high efficiency. Transverse sections of gastrocnemius muscles were 
stained using an antibody against HA (with which hnRNP R was tagged) and a 
fluorescent secondary antibody was used. Analysis of sections under a fluorescent 
microscope showed a large amount of HA-positive muscle fibres (fig. 5.6). 
Untransduced fibres were also present in the muscle sections (fig 5.6, top arrows), 
which demonstrates the specificity of the HA staining. Spinal cord sections were 
also stained using an antibody against HA however no HA-positive cells were 
observed in the stained spinal cord sections. This suggests that the virus is able to 
successfully transduce muscle tissue despite the low transduction efficiency seen in 
the spinal cord. 
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Figure 5.5 AAV6-mediated GFP transduction of lumbar spinal cord in SMNΔ7 mice. A: 
Spinal cord sections stained for GFP show a small number of motor neurons and astrocytes are 
transduced by AAV6-GFP. Scale = 100µm. B: High magnification images of (A), scale = 20µm. 
Figure 5.6 AAV6-hnRNP R transduction of gastrocnemius muscle in SMNΔ7 mice. Muscle 
sections stained for HA (red) and DAPI (blue) show effective transduction of muscle fibres by AAV6-
hnRNP R. Scale = 20µm. The top arrows show untransduced fibres as contrast to the transduced 
fibres indicated by the bottom three arrows. 
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5.3 Discussion 
hnRNP R was identified by our collaborator Michael Sendtner as a direct binding 
partner of SMN and a modifier of SMA phenotype in vitro. We therefore 
hypothesized that overexpression of hnRNP R would rescue the SMA phenotype in 
an in vivo SMA mouse model.   
AAV6-hnRNP R treatment induced a small and marginal effect of survival of SMNΔ7 
mice. Kaplan-Meier survival analysis revealed mean survival of 13.0±0.76 days and 
7.20±1.53 days for AAV6-hnRNP R and AAV6-GFP treated mice respectively. However 
it is worth stating that AAV6-hnRNP R mice did not live any longer than the 
reported lifespan of this knock-out mouse model (average 2 weeks) (Le et al., 
2005).  It is therefore unclear why the mean lifespan of the AAV6-GFP group was 
only 7.20±1.53 days. It would have been useful to include a cohort of uninjected 
SMNΔ7 mice as a further control to determine whether the difference in survival 
between the two groups was due to a positive effect of AAV6-hnRNP R or a 
negative effect of AAV6-GFP.  
Alongside its effects on lifespan of SMNΔ7 mice we investigated motor ability of 
treated animals by assessing their ability to right themselves, as these animals were 
too young for other behavioural motor tests such as rotorod or catwalk analysis. 
The ability to self-right was generally improved in AAV6-hnRNP R injected mice, 
compared to controls. However there was a lot of variability in ability to complete 
the test. Variation was seen between mice in the same group and also between 
days for the same mouse. Therefore success on one day was not predictive of 
success the next day, and success of one mouse was not predictive of success for 
another mouse in the same group. This variation was possibly due to the young 
age of the mice but despite this variation there was a clear trend that AAV6-hnRNP 
R treated mice were better at performing the righting-reflex compared to AAV6-GFP 
controls. 
Another phenotype of SMNΔ7 mice is their slow increase in weight gain; we 
therefore monitored growth of mice by daily measurement of their body weight. This 
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analysis revealed no significant difference between body weight of hnRNP R 
expressing mice and controls. Both these groups had significantly lower body weight 
than carrier littermates. 
The number of motor neurons in the anterior horn of the lumbar spinal cord is 
greatly reduced in SMNΔ7 mice (Le et al., 2005). We were therefore interested to 
assess the impact of hnRNP R gene therapy on spinal motor neuron survival. Cell 
counts of motor neurons in the lumbar spinal cord revealed that there was no 
difference in the number of motor neurons between the two treatment groups.  
Overall there appears to be a small effect of overexpressing hnRNP in SMNΔ7 mice; 
however this effect was much less impressive than that seen in previous studies 
using SMN gene delivery in the SMNΔ7 mouse model (Foust et al., 2010; Passini et 
al., 2010; Valori et al., 2010). These studies used AAV serotype 9 which has been 
reported to lead to widespread gene transfer in the CNS when delivered 
systemically in neonate mice (Foust et al., 2010; Valori et al., 2010). Prior to the 
start of this study using the hnRNP R gene, it was unclear how efficient the AAV6 
vector was in crossing the blood brain barrier in mouse. Gene transfer analysis 
revealed very low number of GFP expressing motor neurons in the lumbar spinal 
cord (less than 5 per animal) and a similar number of GFP-expressing astrocytes. 
hnRNP R expression was also monitored using anti-HA-tag antibodies. Analysis of 
spinal cord sections revealed no HA-positive staining in motor neurons. In order to 
demonstrate that the vector can efficiently transduce other tissues muscle tissue 
was stained with anti-HA. The staining revealed high transduction efficiency of 
muscle fibres with AAV6-hnRNP. Together this study suggests that AAV6 does not 
effectively cross the blood brain barrier when administered systemically in neonate 
mice. 
It is possible that the small effect of AAV6-mediated hnRNP R expression was due 
to very little transduction of lumbar spinal cord motor neurons. The improved 
survival of AAV6-hnRNP R injected mice compared to AAV6-GFP controls and the 
superior performance in the righting reflex suggests there was some positive effect 
of treatment. However this effect was not large enough to alter body weight or 
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survival. It is possible that some positive effect on phenotype was due to 
transduction in other tissues. It has been reported that therapy targeted towards 
SMA needs to affect peripheral tissue as well as the CNS to treat other organs 
effected by SMA (Hua et al., 2011; Hamilton & Gillingwater, 2013). 
In summary the effect of hnRNP R overexpression in SMNΔ7 neonates is 
inconclusive but hnRNP R still a promising candidate as a modifier of SMA. We have 
also demonstrated that AAV6 is not efficient at crossing the blood brain barrier in 
neonate mice. Further work using hnRNP R could be performed using AAV9 as a 
vector for hnRNP R expression since this has previously been shown to efficiently 
restore SMN levels in SMNΔ7 mice (Foust et al., 2010; Passini et al., 2010; Valori et 
al., 2010). 
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Chapter 6  
 
Effect of PTEN Silencing on SMA 
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6.1 Introduction 
Spinal muscular atrophy is characterised by axon degeneration and subsequent 
death of motor neurons. The role of PTEN in negatively regulating cell survival, as 
well as cell size and axon growth suggests that it could be a potential therapeutic 
target for SMA (Stambolic et al., 1998; Kwon et al., 2001; Ning et al., 2010). 
Inhibition of PTEN has been shown to confer resistance to apoptosis as well as 
improve regeneration after nerve injury and in purified motor neurons from an SMA 
mouse model. We therefore hypothesised that widespread silencing of PTEN in the 
spinal cord of SMNΔ7 mice may improve survival of motor neurons and possibly 
enhance axon growth, leading to an overall improvement in survival in this mouse 
model.  
PTEN was first identified as a tumour suppressor gene found mutated in multiple 
cancers including glioblastomas, prostate, kidney and breast cancers (Li et al., 1997) 
and was also named MMAC1 (Steck et al., 1997). The protein was shown to contain 
a tyrosine phosphatase domain and also a region of homology with tensin. Tensin 
is a protein that links actin filaments to integrin receptors and interacts with 
tyrosine-phosphorylated proteins and plays an important role in muscle regeneration 
and cell migration (Lo, 2004). The PTEN protein is made up of 403 amino-acids and 
contains three domains. A phosphatase domain is situated at the N-terminus, with a 
C2 domain involved in lipid-binding and a PDZ ligand sequence at the C-terminus 
(Ross et al., 2001). PTEN also has two PEST sequences that cause proteasomal 
degradation, leading to rapid protein turnover.    
Shortly after identification the protein was shown to be a dual specificity 
phosphatase due to the ability to dephosphorylate serine/threonine and tyrosine 
peptides (Myers et al., 1997). Furthermore it was demonstrated that this protein was 
able to dephosphorylate phosphatidylinositol 3,4,5-triphosphate (PIP3) (Maehama & 
Dixon, 1998; Stambolic et al., 1998). This was consolidated by the finding that 
PKB/Akt is hyperphosphorylated in cells lacking PTEN. PKB/Akt is a promoter of cell 
survival, and activation is dependent on levels of PIP3. In short PTEN inhibits PIP3 
mediated activation of PKB/Akt by dephosphorylating PIP3 to PIP2 (fig. 6.1).  
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Figure 6.1 PTEN function in the PI3K / Akt pathway. PTEN negatively regulates the 
PI3K / Akt pathway by dephosphorylating PIP3 to PIP2. PI3K activates PDK1 to 
phosphorylate Akt, activating the mTOR pathway (among others) to promote cell survival 
and growth.    
 
 
Tissue specific knockdown of PTEN in the brain has been used to investigate the 
function of this protein during brain development. The brains of these mice were 
significantly larger than controls and neurons displayed increased soma size 
(Backman et al., 2001; Kwon et al., 2001). The mice appeared healthy at birth but 
developed seizures and ataxia at the age of 9 weeks. There is some disagreement 
as to whether PTEN knockdown in the brain affects proliferation as some groups 
suggested proliferation was increased (Groszer et al., 2001; Li et al., 2002) but 
others found no difference (Backman et al., 2001; Kwon et al., 2001).  Furthermore 
PTEN-null cells display increased resistance to apoptosis when cells were exposed 
to various apoptosis stimuli (Stambolic et al., 1998), as well as preventing 
excitotoxic death after exposure to glutamate (Gary & Mattson, 2002).  
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Conditional knockdown of PTEN in the brain has been used to further elucidate how 
this protein can affect neurons. PTEN-deficient neurons display increased cell size 
and dendritic spine density alongside enlargement of projections (Kwon et al., 2006; 
Fraser et al., 2008; Luikart et al., 2011). Furthermore PTEN knockdown in PC12 cells 
lead to increased proliferation and survival, and improvement in neurite outgrowth in 
differentiating PC12 cells (Jia et al., 2010). PTEN silencing also ameliorates the 
inhibitory effect that myelin-associated glycoproteins have on neurite outgrowth in 
cortical neurons (Perdigoto et al., 2011). PTEN plays an important role in axon 
outgrowth; knockdown in muscle-nerve co-cultures from xenopus displayed increased 
rate of axon outgrowth after contact with muscle cells (Li & Peng, 2012). Enhanced 
axon outgrowth was also seen in PTEN-null neurons in mice (Kwon et al., 2006).  
Interestingly PTEN-knockdown has been shown to improve axon regeneration 
following nerve injury. Conditional PTEN deletion improved axon regeneration in 
injured corticospinal neurons (Liu et al., 2010), injured adult retinal ganglion cells 
(Park et al., 2008) and drosophila sensory neurons (Song et al., 2012). Furthermore 
when PTEN-null dopaminergic neurons were transplanted into the brains of a mouse 
model of Parkinson’s disease they displayed improved survival and fibre outgrowth 
(Zhang et al., 2012). PTEN depletion was also able to rescue the shortened axons 
of cultured motor neurons purified from SMNΔ7 mice (Ning et al., 2010). PTEN 
depletion in these SMN-null motor neurons also improved survival, increased growth 
cone size and restored levels of β-actin in growth cones. Improvement in survival of 
cultured motor neurons was also translated to improvement in survival of motor 
neurons in vivo following a single injection of AAV6 expressing siPTEN into the 
gastrocnemius muscle of SMNΔ7 mice (Ning et al., 2010).  
To ensure efficient delivery of siRNA against PTEN to the CNS of SMNΔ7 mice we 
used the adeno-associated vector serotype 9 (AAV9) which has been shown to 
rapidly and effectively transduce cells of the CNS after intravenous injection in 
neonatal mice (Zincarelli et al., 2008; Foust et al., 2009; Miyake et al., 2011). Data 
from several independent groups indicates that systemic AAV9 delivery causes 
widespread transduction of neurons and glia in the brain and spinal cord as well as 
128 
 
other cell types in other tissues including heart, muscle and liver (Zincarelli et al., 
2008; Foust et al., 2009; Valori et al., 2010). Furthermore administration of scAAV9 
delivering SMN protein has extended the life-span and ameliorate motor deficits in a 
mouse model of SMA (Bevan et al., 2010; Valori et al., 2010; Dominguez et al., 
2011). We therefore expected that a scAAV9 vector would be able to provide robust 
transduction in the spinal cord and thus cause a significant level of PTEN depletion. 
Self-complementary vectors negate the need for AAV to convert single-stranded DNA 
into double stranded DNA before transgene expression (McCarty, 2008). This means 
that self-complementary vectors can express transgenes faster and more efficiently 
than single-stranded vectors (Wang et al., 2003). 
A self-complementary AAV9 construct was designed using the siRNA sequence as 
previously reported (Ning et al., 2010); this construct also expresses GFP as a 
reporter gene to assess levels of transduction. The siRNA sequence consists of a 
19 nucleotide sequence that target exon 1 of the gene. This sequence generates 
around 60% reduction in PTEN levels in primary motor neurons (Ning et al., 2010).  
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6.2 Results 
SMNΔ7 mice were injected with 10µl (1010 viral particles) of scAAV9-siPTEN (n=10) 
into the facial vein on post-natal day 1. As a control 10 SMNΔ7 mice were also 
injected with scAAV9-scrambled-siPTEN, which expresses the same siRNA construct 
but with the nucleotides in a different order. Untreated SMNΔ7 mice (n=9) and 
carrier (Smn+/+;SMN2+/+;SMNΔ7+/+) littermates (n=6) were also included as further 
controls. The mice were assessed daily throughout their life to determine whether 
there was any effect on phenotype. 
 
6.2.1 Body Weight 
SMNΔ7 is a well-established mouse model of SMA. SMNΔ7 mice are characterised 
by muscle weakness and die within 2 weeks of age (Le et al., 2005). A major 
aspect of the phenotype of SMNΔ7 mice is slow growth and body weight decrease 
from postnatal day 8 (El-Khodor et al., 2008). We therefore measured how the body 
weight of these mice changed over time. Mice injected with scAAV9-siPTEN displayed 
slow weight gain, however body weight continued to increase after postnatal day 9 
when the body weight of scAAV9-scrambled-PTEN controls began to fall (fig. 6.2 B). 
scAAV9-siPTEN treated mice had significantly higher bodyweight than scAAV9-
scrambled-siPTEN controls from day 12 onwards (p<0.05, two-way ANOVA). Body 
weight measurement revealed that scAAV9-siPTEN treated mice continued to 
increase steadily throughout their life, but remained approximately half the weight of 
healthy carriers. Carrier littermates had significantly higher body weights than 
scAAV9-siPTEN treated animals from day 20 onwards (p<0.05, two-way ANOVA).  
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Figure 6.2 scAAV9-siPTEN improves growth in SMNΔ7 mice. A: Pictures showing the same 
SMNΔ7 pups at different ages, as indicated. A gender-matched carrier littermate is included in 
each picture for reference. The pups were injected at postnatal day 1 with either scAAV9-
siPTEN or scAAV9-scrambled-siPTEN. B: Body weight growth in SMNΔ7 injected with 
scAAV9-siPTEN (n=10) or scAAV9-scrambled-siPTEN (n=10). Untreated and carrier groups 
were included as controls. * p<0.05, ** p<0.01, scAAV9-scrambled-siPTEN versus scAAV9-
siPTEN, # p<0.05, ## p<0.01, ### p<0.001, #### p<0.0001, carrier versus scAAV9-siPTEN, 
two-way ANOVA with Bonferroni post-hoc test. 
 
6.2.2 Righting Reflex 
A righting-reflex test was used to assess the general motor function of treated 
SMNΔ7 mice. The test was performed daily and assessed whether animals were 
able to move themselves onto their paws after being placed on their backs. If the 
animal was able to do this within 30 seconds it was deemed successful (El-Khodor 
et al., 2008). The number of mice able to successfully right themselves in the 
scAAV9-siPTEN treatment group increased steadily and reached 100% at 15 days 
(fig. 6.3). In comparison the scAAV9-scrambled-siPTEN controls were unable to 
complete the test on the majority of days, with the highest level of success being 
littermate 
littermate littermate scAAV9-siPTEN 
scAAV9-
scrambled- 
 siPTEN 
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scrambled- 
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20% on two non-consecutive days (fig. 6.3). The number of scAAV9-siPTEN treated 
animals able to compete the righting-reflex test was significantly higher (p<0.05, two-
way ANOVA) than scAAV9-scrambed-siPTEN treated animals from day 15. The ability 
of carrier littermates to complete the test was also assessed and all carriers were 
able to successfully complete the test from day 2 onwards. There was no significant 
difference between the ability of scAAV-siPTEN mice to complete the test and the 
ability of carrier animals to complete the test from day 8 (p>0.05, two-way 
ANOVA).The outcome of this behaviour test demonstrates a robust improvement in 
the phenotype of mice injected with scAAV9-siPTEN over time.    
 
 
 
 
 
 
6.2.3 Survival 
As well as assessing body weight and motor function mice were monitored daily for 
any signs of ill health. The tails of scAAV9-siPTEN mice were shorter and thicker 
than healthy littermates and as the animals aged the tails appeared to develop 
Figure 6.3 Motor function assessment in rescued SMNΔ7 mice. Percentage of mice 
able to complete the righting reflex test. Mice were placed on their backs and were deemed 
successful if they were able to re-orientate within 30 seconds. scAAV9-siPTEN injected 
mice improved gradually over the first 15 days of age. * p<0.05, scAAV9-siPTEN versus 
scAAV9-scrambled-siPTEN, ## p<0.01, scAAV9-siPTEN versus carrier, two-way ANOVA 
with Bonferroni post-hoc test.  
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necrosis. The ears of these mice also became red and inflamed and they too 
developed necrosis. This has previously been reported in rescued SMNΔ7 mice and 
is thought to be a secondary phenotype caused by the disease, rather than an 
effect of the scAAV9 delivery (Narver et al., 2008; Foust et al., 2010; Passini et al., 
2010; Valori et al., 2010; Dominguez et al., 2011; Hua et al., 2011).  
When treated mice began to exhibit reduced provoked behaviour and lack of 
grooming alongside a slight reduction in body weight of approximately 10-30% they 
were humanely culled. They were still successfully able to complete the righting 
reflex test at this point; however it was observed that some mice dragged their 
hind-limbs as they walked. Kaplan-Meier analysis was performed to assess the 
survival time of scAAV9-siPTEN treated mice compared to scAAV9-scrambled-siPTEN 
treated controls (fig 6.4). This analysis showed a significant increase in lifespan 
following treatment with scAAV9-siPTEN (fig 6.4), compared to mice injected with 
scAAV9-scrambled-siPTEN. Mean survival for scAAV9-siPTEN treated mice was 
30.4±7.4 days compared to 9.2±1.5 days for scAAV9-scrambled-siPTEN injected mice 
(p<0.01, one-way ANOVA with Tukey’s post-hoc test) and 10.56±1.42 for untreated 
SMNΔ7 mice. The longest surviving treated mouse lived for 74 days, and 60% of 
mice injected with scAAV9-siPTEN lived for longer than any of the scAAV9-
scrambled-PTEN controls. However four scAAV9-siPTEN injected mice did not display 
any improvement in survival. The data from these animals were still included in the 
body weight (fig. 6.3) and righting reflex analysis (fig 6.4). 
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Figure 6.4 Kaplan-Meier survival curve. This graph summarises survival times for scAAV9-
siPTEN injected animals (n=10) compared with scAAV9-scrambled-siPTEN (n=10) and uninjected 
SMNΔ7 controls (n=9). p<0.01 scAAV9-scrambled-siPTEN verses scAAV9-siPTEN, log-rank 
(Mantel-Cox) test. Mice injected with scAAV9-siPTEN lived significantly longer than scAAV9-
scrambled-siPTEN (p<0.01) and SMNΔ7 controls (p<0.05) (one-way ANOVA with Tukey’s post-
hoc test). 
 
  Figure 6.5 scAAV9-siPTEN causes transduction of motor neurons and a reduction in 
PTEN expression. Immunohistochemistry of lumbar spinal cord sections showing CGRP labelled 
motor neurons (red), GFP positive cells (green), and PTEN expression (blue). GFP expression 
demonstrates robust transduction of motor neurons with both vectors used. The staining confirmed 
PTEN depletion in GFP positive motor neurons of the scAAV9-siPTEN injected group compared to 
scAAV9-scrambled-siPTEN controls. Scale bars = 20µm 
CGRP GFP PTEN Merge 
siPTEN 
Scrambled-
siPTEN 
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6.2.4 Transduction and PTEN Depletion in Spinal Cord Motor Neurons 
We hypothesized that the increased survival observed was due to the effect of 
PTEN depletion in spinal cord motor neurons. Immunohistochemistry was therefore 
used to confirm whether spinal cord motor neurons were transduced, and to 
determine the efficacy of scAAV9-siPTEN in mediating PTEN silencing. The viral 
vector used also expresses GFP to enable identification of transduced cells. Lumbar 
spinal cord sections were stained and imaged with help from Dr K. Ning. To assess 
gene transfer an antibody targeted to GFP was used to detect cells that had been 
transduced, whilst an antibody against PTEN was used to assess PTEN expression 
levels. GFP transgene expression was observed in both scAAV9-siPTEN and scAAV9-
scrambled-siPTEN injected animals, displaying that both vectors cause transduction 
(fig 6.5). GFP-positive cells in scAAV9-siPTEN treated animals displayed reduced 
PTEN fluorescence compared to those in scAAV9-scrambled-siPTEN controls.   
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6.2.5 Motor Neuron Survival 
To investigate whether PTEN knockdown improves the survival of motor neurons in 
SMNΔ7 mice spinal cord sections were stained for the motor neuron specific marker 
calcitonin gene-related peptide (CGRP) and positive cells were counted (fig. 6.6 A). 
Staining and counting was performed with help from Dr K. Ning who was blinded to 
treatment groups. Because the main aim of this study was to determine whether 
scAAV9-siPTEN could affect survival the spinal cords used to assess motor neuron 
survival were from mice of different ages. The three spinal cords from the scAAV9-
siPTEN group were from animals aged 25, 29 and 75 days whereas the spinal cords 
from the scAAV9-scrambled-siPTEN group were from once mouse aged 10 days and 
two mice aged 13 days. The number of CGRP positive cells per section in the 
lumbar spinal cord was significantly greater in spinal cord sections of mice injected 
with scAAV9-siPTEN (n=3), compared to that of scAAV9-scrambled-siPTEN controls 
(n=3, fig. 6.6 B p<0.01).  
 
Furthermore some spinal cord sections were stained with an antibody against GFP 
alongside CGRP staining and the number of GFP-positive and GFP-negative motor 
neurons was assessed (fig. 6.6 C). This revealed that the increase in motor neuron 
numbers can be attributed to increased numbers of GFP-positive cells, as the 
number of untransduced cells was the same in scAAV9-siPTEN sections and scAAV9-
scrambled-siPTEN controls. Therefore the improvement in survival of spinal motor 
neurons was due to transduction by AAV9-siPTEN. The data suggests that PTEN 
depletion can reduce cell death in motor neurons of SMNΔ7 mice.  
 
Quantification of GFP-positive motor neurons enabled the transduction efficiency of 
scAAV9-siPTEN and scAAV9-scrambled-siPTEN to be calculated (fig. 6.6 D). This 
revealed that 68.22% and 51.05% of spinal motor neurons were transduced by 
scAAV9-siPTEN and scAAV9-scrambled-siPTEN respectively. The difference in levels of 
transduction can be attributed to the improved survival of motor neurons 
transduced with scAAV9-siPTEN compared to scAAV9-scrambled-siPTEN.   
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Figure 6.6 Effect of PTEN depletion on motor neuron survival in the spinal cord of SMNΔ7 
mice. Lumbar spinal cord sections were stained for CGRP and GFP to quantify motor neuron 
number and transduction efficiency. A: representative images of the ventral horn of the lumber 
spinal cord of treated animals, stained with anti-CRGP (red). Scale bars = 20µm. B: Quantification 
of mean number of CRGP-positive cells per section. **p<0.01, t-test, n=3. C: Quantification of 
mean number of GFP-positive and GFP-negative spinal motor neurons per section. * p<0.05 
(GFP positive cells), t-test, n=3. D: Mean percentage of spinal motor neurons that were GFP 
positive per section. * p<0.05, t-test, n=3. 
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6.3 Discussion 
The data here reveals that a single injection of a scAAV9 expressing siRNA targeted 
against PTEN is sufficient to reduce PTEN levels in lumbar spinal cord motor 
neurons and attenuate motor deficits in a mouse model of SMA. PTEN reduction 
lead to a significant increase in the number of motor neurons in the spinal cord 
compared to animals injected with scAAV9-scrambled-siPTEN. Furthermore animals 
treated with scAAV9-siPTEN displayed significantly longer survival times than scAAV9-
scrambled-siPTEN controls. Mean lifespan of siPTEN treated mice was 30.4±7.4 days 
compared to 9.2±1.5 days for animals that received the scrambled-siRNA control 
vector. The longest surviving mouse lived to 74 days, compared to 14 days for 
scAAV9-scrambled-siPTEN injected controls, which is an increase in maximum 
lifespan of 428%, with a mean increase in lifespan of 230%.   
Four of the 10 mice injected with scAAV9-siPTEN displayed no improvement in 
lifespan compared to controls. The reason for this has not been elucidated however 
it may be due to inefficient gene transfer as previously reported (Valori et al., 
2010). This was reasoned to be due to technical failure during intravenous delivery 
of the vector. Western blot or QPCR could have been used to detect GFP protein 
or mRNA levels in the organs of mice that showed no improvement following 
scAAV9-siPTEN injection. This would have determined whether inefficient vector 
delivery was the cause of this lack of improvement. Due to the small size of mice 
at postnatal day one, efficient intravenous delivery can be challenging. Therefore it 
may be necessary to improve intravenous administration technique for further 
studies. It would be useful to check transduction levels in the mice that displayed 
no response to treatment to determine how efficient gene transfer was in these 
mice. 
Furthermore within the mice that did show an improvement in lifespan there was 
variability, with three mice being sacrificed between 22 and 29 days old and three 
mice living for between 45 and 75 days. Variability in improvement of lifespan was 
also observed in two other studies that used scAAV9 to express SMN (Valori et al., 
2010; Dominguez et al., 2011). Interestingly however there was no observed 
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difference in transduction efficiency or motor neuron numbers between mice that 
died at 25, 29 and 75 days. This suggests there may be other external influences 
on how well these mice thrive and how long they live.  
Alongside survival an amelioration of phenotype in rescued animals was observed. 
PTEN deficient animals displayed robust weight gain, coupled with improved motor 
function comparable to that of carrier littermates when assessed by righting-reflex 
test.  During early life the scAAV9-siPTEN treated animals were indistinguishable 
from scAAV9-scrambled-siPTEN controls in terms of size and appearance. By day 10 
however the siPTEN treated animals were performing better at the motor function 
test, and were continuing to gain weight, unlike the control animals, whose weight 
began to fall. As scrambled-siPTEN controls began to appear moribund, the siPTEN 
treated animals continued to perform well and looked healthy, albeit smaller than 
carrier littermates. This suggests that it took some time for the viral vector to 
express siRNA and cause an effect.  
Although AAV9-siPTEN somewhat rescued the phenotype of these SMNΔ7 mice they 
were obviously different to carriers. As mentioned they were smaller than carrier 
littermates, with body weight peaking at 15g for the longest surviving mouse, 
compared to a peak weight of 29g for a 75 day old carrier. Furthermore the tails 
of these rescued mice were shorter and thicker than carrier littermates. This defect 
was not apparent from birth but became more obvious as the animals grew and 
their tails did not lengthen. As the rescued animals aged their tails began to show 
signs of necrosis, at around the same time the ear of these animals became red 
and inflamed and they too began to display necrosis.  This phenotype has been 
reported previously in rescued SMNΔ7 mice (Valori et al., 2010; Dominguez et al., 
2011) and also in SMA patients (Araujo et al., 2009; Rudnik-Schoneborn et al., 
2010). Distal necrosis is thought to be due to SMN deficiency affecting vasculature 
however the full reason for this has not yet been resolved. Unfortunately PTEN 
depletion was not able to rescue these defects, either because the abnormalities 
occur during early development or because siRNA expression was not high enough 
in these areas.  
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Further work needs to be undertaken to fully understand how PTEN knockdown 
improved survival of these SMNΔ7 mice. The increase in motor neuron numbers 
seen in the spinal cord suggests that PTEN knockdown improves survival in these 
cells. Immunofluorescence was used to demonstrate reduction in PTEN levels in 
motor neurons of the lumbar spinal cord. It may have been possible to quantify the 
level of PTEN silencing in the lumbar spinal cord by QPCR, however this method 
may not be sensitive enough to detect a reduction PTEN levels due to the relatively 
large number of cells in the spinal cord that are not transduced. It would be 
possible to use laser capture microdissection (LCM) to isolate only motor neurons 
from spinal cords for QPCR in order to improve sensitivity. However LCM is very 
time consuming and it may be difficult to isolate enough motor neurons to have 
sufficient quantities of mRNA for QPCR. The improvement in motor neuron survival 
seen here corroborates with previously published data showing that PTEN silencing 
can improve motor neuron survival in vivo following intramuscular injection of AAV6 
expressing siPTEN (Ning et al., 2010). It would have also been of interest to 
determine the level of motor neuron survival in the cervical spinal cord as these 
cells are also affected by SMA, however time constraints meant only the lumbar 
spinal cord was analysed.   
Previous in vitro data also shows that axons of cultured motor neurons from 
SMNΔ7 mice have longer axons, larger growth cones and increased β-actin levels 
(Ning et al., 2010). This suggests that axon length may also be increased in motor 
neurons in vivo although this is yet to be determined. Defects in axon outgrowth in 
SMA are thought to be due to impaired trafficking of β-actin and reduced SMN 
levels in the growth cone. This leads to abnormalities at the synapse and 
neuromuscular junction. Therefore it can be expected that silencing PTEN in vivo will 
have a similar effect as in cultured motor neurons and improve axon length by 
increasing β-actin levels in the growth cone. 
Our results show that it is possible to improve the phenotype of SMA mice without 
directly targeting the SMN protein through silencing of PTEN. This builds upon 
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previously published research showing that silencing PTEN can improve motor 
neuron survival (Ning et al., 2010).  
The increase in life-span seen here was not as impressive as has been reported in 
studies overexpressing SMN (Bevan et al., 2010; Foust et al., 2010; Valori et al., 
2010; Dominguez et al., 2011). However the use of PTEN knockdown to improve 
motor neuron survival suggests a possible option for increasing survival in a variety 
of degenerative diseases such as motor neuron disease, Parkinson’s disease and 
Alzheimer’s disease. Interestingly, a previous study has demonstrated that PTEN 
knockdown in dopaminergic neurons can rescue motor deficits in two mouse 
models of Parkinson’s disease (Domanskyi et al., 2011). PTEN silencing could also 
be used as a combination therapy alongside SMN overexpression.  
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Chapter 7  
 
DISCUSSION 
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SMA is a genetic disease caused by recessive mutations in a single SMN gene 
(Lefebvre et al., 1995). Gene therapy therefore represents an attractive approach for 
SMN replacement in this devastating disease (Lefebvre et al., 1995; Foust et al., 
2010; Passini et al., 2010; Valori et al., 2010; Dominguez et al., 2011; Benkhelifa-
Ziyyat et al., 2013). To achieve successful gene therapy for SMA, widespread 
delivery of therapeutic genes to the CNS is required. There appears to be other 
disease-modifying genes that also could be targeted for gene therapy-mediated 
treatment for SMA including hnRNP R and PTEN (Rossoll et al., 2003; Ning et al., 
2010). This project had two broad aims: i) to assess different vector systems for 
gene therapy and ii) to investigate the possibility of rescuing SMA phenotype 
through SMN-independent targets. Four different vector systems were tested in this 
project; three serotypes of AAV, namely AAV5, AAV6 and AAV9 as well as a non-
viral delivery system, polymersomes. Furthermore we explored novel therapeutic 
strategies for SMA by modulation of disease modifying genes, hnRNP R and PTEN. 
 
7.1 Project Outcomes 
The use of polymersomes as a non-viral delivery method for gene therapy 
represents a novel technology. We therefore believe that this approach will need 
extensive optimisation before being ready for in vivo applications. DNA encapsulation 
within polymersomes have previously been reported (Lomas et al., 2007; Lomas et 
al., 2010), but never tested for therapeutic strategies. Here we show encapsulation 
occurs in a size-dependent manner with larger vesicles being able to encapsulate 
more DNA. Furthermore centrifugation was used to sort polymersomes based on 
size. This enabled the exclusion of polymersomes with low encapsulation thus 
increasing the amount of encapsulated DNA. Luciferase was used as a reporter 
plasmid and delivered to HEK293T cells resulting in luciferase expression. A linear 
relationship was seen between the amount of luminescence detected and the 
amount of encapsulated DNA in the polymersomes used for transfection. We can 
therefore conclude from this study that polymersomes encapsulate DNA in a size 
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dependant manner and transduction is directly related to the amount of 
encapsulated DNA. 
Polymersomes were then used to drive overexpression of SMN through the 
encapsulation of SMN plasmid DNA and transfection of HEK293T cells and 
fibroblasts derived from a SMA type I child. Transfection of HEK293T cells resulted 
in a 2.6-fold increase in SMN protein levels and a 38-fold increase in SMN mRNA 
levels. Furthermore SMN mRNA levels were increased 367-fold in SMA fibroblasts. 
SMN restoration in SMN-deficient fibroblasts was confirmed by immunofluorescence. 
Therefore we can conclude that polymersomes are able to deliver gene therapy for 
spinal muscular atrophy in vitro. However this technology will need further 
optimisation before use for in vivo applications. In particular the main challenge is 
to target polymersomes to penetrate the BBB and reach target cells such as motor 
neurons. 
The ability of AAV5 to transduce CNS tissue following neonatal IV injection was 
investigated in a pilot study. Two vector systems were used with different 
promoters, CAG and CMV. The vector system incorporating the CMV promoter 
produced almost no transduction in the CNS. A modest amount of transduction was 
seen in the brain and a small number of transduced cells were detected in the 
lumbar spinal cord with AAV5-CAG-GFP. Interestingly the highest level of transduction 
in the brain appeared to be of cells within the ventricles whilst the highest level of 
transduction in the spinal cord was seen in the dorsal root. Throughout the brain 
and lumbar spinal cord GFP-positive fibres were detected which appeared to be 
axons. There also appeared to be some tropism of AAV5 for white matter tissue 
within the CNS. This pilot study revealed that AAV5 mediates poor gene transfer 
efficiency in the CNS following IV delivery in neonate mice. Based on this result we 
decided not to use this AAV5 vector for further in vivo studies.  
AAV6 was used to express hnRNP R in SMA mice since it was hypothesized that 
hnRNP R may be a disease modifier of SMA and over expression would improve the 
phenotype of these mice. A small increase in survival was seen following AAV6-
hnRNP R administration compared to controls injected with AAV6-GFP. However, no 
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difference was seen between the lifespan of treated mice compared to the reported 
lifespan of this mouse model (Le et al., 2005). A slight improvement in the motor 
function of these mice was observed by testing their ability to right themselves. 
Unfortunately there was no difference in the body weight of treated mice compared 
to controls. Furthermore when the number of motor neurons in the lumbar spinal 
cord was counted there was no significant difference between motor neuron survival 
in treated mice and controls. Assessment of the level of transduction in the lumbar 
spinal cord revealed very low transduction despite robust transduction seen within 
the gastrocnemius muscle. This low level of motor neuron transduction suggests a 
possible reason for the modest effect seen on phenotype and motor neuron 
survival. Therefore hnRNP R remains a candidate as a disease modifier for SMA 
however more effective gene transfer to the CNS is necessary to achieve robust 
conclusions over how hnRNP R expression can affect SMA phenotype. This study 
shows that AAV6 does not transduce motor neurons well following intravenous 
neonatal injection. 
Another possible disease modifier of SMA is PTEN; knockdown of which leads to 
increased motor neuron survival following intramuscular injection (Ning et al., 2010). 
We therefore used AAV9 to express siRNA directed towards PTEN by IV injection in 
neonatal SMA mice. This gene therapy approach resulted in a significant increase in 
survival in SMNΔ7 mice with the average survival time of siPTEN treated mice being 
30.4±7.4 compared to 9.2±1.5 for scrambled-siPTPEN controls. The phenotype of 
treated mice was also improved as shown by body weight gain and righting-reflex 
performance. Furthermore animals treated with AAV9-siPTEN had a significantly 
greater number of lumbar spinal cord motor neurons than controls at disease 
endstage.  
This shows that PTEN is a disease modifier of SMA and silencing PTEN can improve 
phenotype of SMA mice and increase their survival. The significant increase in motor 
neuron numbers in the lumbar spinal cord suggests a mechanism by which 
improved survival was mediated. Moreover immunofluorescence analysis of the 
lumbar spinal cord revealed that AAV9 mediated robust transduction of motor 
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neurons with a resulting reduction of PTEN protein levels in transduced cells. This 
correlates with previous studies that have successfully used AAV9 for gene therapy 
to the CNS to successfully treat SMA (Foust et al., 2010; Valori et al., 2010; 
Dominguez et al., 2011). 
 
7.2 Further Considerations 
 
7.2.1 Polymersomes as Gene Therapy Vectors 
We have shown that polymersomes can encapsulate DNA in a size dependent 
manner through sorting polymersomes by size using centrifugation. However size 
distribution data shows that centrifugation is not wholly effective in separating 
different sized polymersomes. Therefore it may be possible to further improve the 
concentration of encapsulated DNA by improving the efficiency of sorting of 
polymersomes by size. It is possible to separate different sized polymersomes by 
other methods such as gel permeation chromatography or hollow-fibre filtration 
(Rameez et al., 2010). It may also be possible to create polymersomes with a 
greater propensity to form larger particles by changing the block copolymer lengths 
or adjusting how the polymersomes are made. However larger polymersomes have 
slower uptake kinetics than small polymersomes which may have consequences for 
transfection efficiency. Interestingly polymersomes can be formed by using two 
different block-copolymers to create polymersomes with different surface domains 
(Massignani et al., 2009). These patches cause large polymersomes to have fast 
uptake kinetics like small polymersomes.   
Transfection of cells by polymersomes was shown to be dependent on the amount 
of encapsulated DNA therefore improving the amount of encapsulated DNA in a 
polymersome solution should improve the level of transfection achieved. 
Polymersomes used for the overexpression study were centrifuged at 10000 rcf in 
order to collect as many polymersomes that have encapsulated DNA. However size-
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sorting data suggests that a higher level of transfection could have been achieved 
by only using polymersomes centrifuged at a low speed.  It therefore may be 
possible to increase the level of SMN over-expression achieved by selecting only the 
largest polymersomes and thus delivering a higher amount of DNA.  
Another way of improving encapsulation could be to increase the amount of DNA 
added to the polymer solution. Throughout the characterisation of encapsulation the 
same amount of DNA was added to the solution, therefore increasing the amount 
of DNA added to the polymer solution could increase the encapsulation efficiency. 
There is likely to be an optimum concentration of DNA to be added to polymer 
solution to be encapsulated, above which no more DNA would be encapsulated. It 
would therefore be interesting to assess the level of encapsulation following 
addition of different amounts of DNA. We have shown that polymersomes can be 
used in vitro to restore SMN protein and mRNA levels in SMN-deficient fibroblasts. 
The next challenge is to design polymersomes that could cross the BBB and widely 
deliver SMN to the CNS in an in vivo model of SMA.  
7.2.2 AAV5 Transduction in the CNS 
AAV5 was shown to transduce brain and spinal cord tissue with low efficiency using 
the CAG promoter however almost no transduction was seen with the CMV 
promoter. The reason for this difference has yet to be elucidated. It would be 
useful to check transduction levels in other tissues such as the liver which is highly 
transduced by AAV5 (Zincarelli et al., 2008) in order to check that the AAV5-CMV-
GFP vector was working correctly. It would also be interesting to check transduction 
levels in other tissues to determine whether the variation seen in transduction in 
the CNS was also present throughout all tissues. The level of variation in 
transduction between animals meant that it was challenging to compare the effect 
of the two time-points since only a small number of animals were used in this pilot 
study and some animals displayed no transduction. Furthermore it may also be 
necessary to use more time points to analyse the time course of transduction for 
AAV5. However we have shown here that transduction efficiency within the CNS is 
low and AAV5 does not appear to pass the BBB therefore there would not be much 
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benefit in further investigating the use of AAV5 for gene therapy applications in 
SMA.  
The high level of transduction seen in the dorsal root was interesting and it may 
be worth investigating this further. It would have been very useful to dissect the 
dorsal root ganglia separately in order to investigate the level of transduction here. 
However the aim of the project was to investigate gene therapy for SMA therefore 
the focus was on transduction within the lumbar spinal cord. Unfortunately we did 
not dissect the DRG to investigate the level of transduction here but fortunately we 
could see some of the dorsal root attached to the spinal cord sections.  
Furthermore it appeared that transduction within the spinal cord may be mediated 
through the retrograde transport of the vector up the dorsal root, as suggested by 
the transduction of cells and fibres near the highly transduced dorsal root. It would 
therefore be interesting to assess the ability of AAV5 to undergo retrograde 
transport by administering AAV5 by intramuscular injection to the gastrocnemius 
muscle for example and assessing the level of transduction within the spinal cord, 
dorsal root and even in sensory nerves. AAV5 has been previously used to drive 
transgene expression in the spinal cord following intramuscular injection of the 
gastrocnemius (Petruska et al., 2010). However it is unclear if motor neurons could 
be transduced efficiently enough for treatment of SMA. 
As mentioned this pilot study only used a small number of animals in each group, 
which coupled with the variation makes it difficult to make confident conclusions. 
Only a small number of animals were used as this was a pilot study to test 
whether AAV5 could transduce the CNS, with the aim of following up any positive 
results in a larger study. We used 3 animals per group so it would still be possible 
to perform statistics of transduction efficiency results however the variability 
between animals was unexpected. Transduction was assessed by 
immunofluorescence using glial and neuronal markers to ascertain the cell types 
that had been transduced. However there were a number of transduced cells that 
did not co-localize with either the glial or neuronal markers it would have therefore 
been useful to use more markers to fully ascertain what cells these were. For 
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example it is assumed that the small GFP-positive fibres seen throughout the CNS 
were axons however this has not been confirmed. Furthermore it would be 
interesting to elucidate exactly what was transduced within the ventricles of the 
brain, and the transduction within the dorsal root and other white matter areas of 
the spinal cord.  
 
7.2.3 AAV9-mediated silencing of PTEN 
PTEN was shown to be a modifier of SMA, possibly through increasing survival of 
lumbar spinal cord motor neurons. Unfortunately 4 of the 10 animals injected did 
not show any improvement in survival. These animals were included in the body 
weight data and the motor function data, but were not included in the histological 
analysis and motor neuron survival data. The three animals used for 
immunofluorescence and motor neuron survival lived for 75, 29 and 25 days. It 
would be very interesting to use Western blot or QPCR to check the level of gene 
transfer in the animals that did not display any improvement in phenotype to 
determine whether the injection and gene transfer was at all successful. Furthermore 
it would also be interesting to ascertain the level of gene transfer between the 
other animals as there was some difference in survival times. This could be due to 
variation in the amount of vector administrated, or could be due to other factors 
influencing how well the animals thrived such as litter size or ability to feed after 
weaning. 
We have shown that PTEN silencing improves survival of motor neurons but it would 
be interesting to see whether AAV9-mediated PTEN reduction affects other tissues. 
This may be important as there is a growing body of evidence showing that SMA is 
a multi-system disorder affecting many tissues (Hamilton & Gillingwater, 2013). For 
example patients and mouse models have been shown to display cardiac defects 
(Rudnik-Schoneborn et al., 2008; Heier et al., 2010; Shababi et al., 2010). Patients 
and mouse models both also display pancreas defects including hyperglycemia 
(Bowerman et al., 2012) and liver defects have also been reported in a mouse 
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model of SMA (Vitte et al., 2004; Hua et al., 2011). Interestingly AAV9 has shown to 
generate robust gene transfer in the heart, liver, muscle and lung (Zincarelli et al., 
2008). It can therefore be expected that AAV9 would mediate PTEN reduction in 
these tissues as well as in the spinal cord. The widespread transduction profile of 
AAV9 suggests that this vector would be suitable to deliver gene therapy for SMA 
since it can transduce many of the tissues effected by the disease. Since PTEN is a 
known tumour suppressor (Li et al., 1997; Di Cristofano & Pandolfi, 2000),  it would 
be necessary to check for the presence of any cancer markers throughout various 
tissues especially those known to be highly transduced by AAV9 such as the heart 
and liver. However the fact that the siRNA used does not generate a full knockdown 
of PTEN but rather achieves a reduction of around 60% (Ning et al., 2010) may 
reduce this risk of tumour development. 
 
7.2.4 AAV6-mediated expression of hnRNP R 
The study into whether hnRNP R could modify the SMA phenotype in vivo was 
inconclusive due to inefficient gene transfer in the CNS by AAV6. It may have been 
possible to produce a more reliable conclusion of the study by performing more in 
vivo tests (El-Khodor et al., 2008). Despite a lack of improvement in body weight or 
survival a positive effect was seen in performance in the righting-reflex test. 
Therefore if we had applied other tests to assess phenotype improvement in these 
mice we may have been able to confirm this positive effect (El-Khodor et al., 2008). 
However it since the effect on phenotype was very mild these test must be 
sensitive. Two other tests of motor function was carried out on these SMA mice 
however there was too much variability in the performance of controls in this these 
two tests that they were not useful in detecting small changes in phenotype. This 
highlights the difficulties in assessing small changes in phenotype of these mice.  
It is clear that AAV6 does not transduce motor neurons sufficiently to be a suitable 
gene therapy vector to treat SMA. AAV9 however has been previously used 
successfully to treat SMA (Foust et al., 2010; Valori et al., 2010; Dominguez et al., 
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2011) and the results from this PTEN study corroborate with previous studies 
showing that AAV9 is an ideal vector for treatment of SMA. Therefore to better 
assess the ability of hnRNP R overexpression to modify SMA phenotype the gene 
should be cloned into an AAV9 vector to achieve better transduction of spinal cord 
motor neurons. This would also provide a better opportunity to compare the 
efficacy of hnRNP R overexpression to SMN overexpression and also to PTEN 
silencing.   
It may have been useful to assess transduction efficiency and the effect of AAV6-
mediated hnRNP R overexpression in other tissues. For example it is known that 
AAV6 transduces skeletal muscle with high efficiency (Zincarelli et al., 2008), which 
was confirmed here by immunofluorescence in the gastrocnemius muscle. It would 
be interesting to assess SMN levels in the muscle tissue as hnRNP R overexpression 
has been shown to increase SMN levels. Furthermore increased SMN levels in the 
muscles may ameliorate the SMA phenotype to some degree. Therefore the slight 
improvement in phenotype observed could be due to transduction in the muscle. 
Muscle specific over-expression of IGF-1 has been shown to increase survival in SMA 
mice suggesting it may be possible to affect the SMA phenotype through targeting 
muscle tissue (Bosch-Marce et al., 2011). However, expressing SMN in muscle alone 
has been shown to have no effect on phenotype or survival (Gavrilina et al., 2008). 
 
7.3 Conclusions 
We have shown that AAV9-mediated PTEN silencing can improve the phenotype of a 
mouse model of SMA. AAV6-mediated hnRNP R expression was not able to achieve 
a similar result possibly due to the inefficiency of AAV6 to transduce spinal cord 
motor neurons following IV delivery. Furthermore we have shown that AAV5 cannot 
pass the BBB well following neonatal IV injection and does not efficiently transduce 
motor neurons therefore is not a suitable candidate for a gene therapy vector 
system to treat SMA. High transduction of the dorsal root and transduction of 
axons within the CNS may however be of some interest for targeting of sensory 
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neurons. Finally we have shown that polymersomes encapsulate plasmid DNA in a 
size-dependent manner. These polymersomes can be used as a non-viral gene 
delivery system to increase SMN in vitro. However further optimisation may be 
necessary before they can be successfully used for gene transfer in vivo. 
 
7.4 Future Perspectives 
As mentioned above there are various points that could be addressed to further 
this project and advance the outcomes stated here which time constraints have 
restricted. Furthermore the results outlined here point towards future directions that 
could be taken to build upon the results of this project. The use of PTEN silencing 
to ameliorate the phenotype of SMA mice and extend their lifespan demonstrates 
that PTEN is a disease modifier of SMA. Following on from this work should be 
undertaken to determine the exact mechanism by which PTEN improves survival in 
this SMA model. We have shown that siPTEN can improve motor neuron survival in 
these mice, as has been shown previously (Ning et al., 2010). This study builds on 
the work of Ning et al., 2010 by demonstrating that PTEN silencing is sufficient to 
improve the phenotype of a mouse model of SMA and significantly improve survival 
in these mice. However it is possible that there are  other mechanisms that also 
contribute to the improvement in survival that are yet to be elucidated.  
For example PTEN also interacts with β-actin in the actin-remodelling complex to 
control cell size. β-actin has been shown to be disturbed in SMA and may be a 
cause of motor neuron dysfunction (Rossoll et al., 2003). Therefore silencing of 
PTEN may improve cell growth including axon outgrowth to increase survival in SMA. 
Furthermore PTEN also inhibits cell migration through the ERK/MAPK pathway and 
migration of motor neurons is also perturbed in SMA, so silencing of PTEN could 
also affect this. PTEN could also indirectly affect SMN levels, possibly through the 
mTOR pathway due to the involvement of mTOR in protein synthesis. Interestingly 
IGF-1 levels are known to be decreased in SMA and IGF-1 can increase levels of 
phosphorylated Akt (Goto et al., 2009).     
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Furthermore as mentioned above it would be useful to use AAV9 to assess the 
effect of overexpressing hnRNP R on SMNΔ7 mice. The data shown here coupled 
with in vitro data from collaborators suggests that hnRNP R can modify the SMA 
phenotype. Therefore with the level of transduction generated by AAV9 it would be 
possible to assess how well hnRNP R overexpression can compensate for SMN 
deficiency in vivo.  
We have shown that polymersomes are an emerging technology that can be used 
for in vitro delivery of gene therapy. With a small amount of further optimisation 
this technology could be used to achieve gene transfer in vitro. The polymersomes 
used in this project were made from PMPC-PDPA which was chosen as it is 
internalised by cells in a short space of time (Lomas et al., 2008). However for 
delivery to the CNS it may necessary to use a polymer with a longer circulation 
time that is decorated with a peptide ligand.   
Decoration of the outside of polymersomes with a peptide could initiate receptor 
binding at the BBB causing transcytosis across the endothelium and into the CNS. 
For example it may be possible to use peptides bound to the polymersome surface 
to imitate the VR-I and VR-IV amino acids on the surface of AAV9 that are thought 
to confer the ablity to pass the blood brain barrer to this vector (DiMattia et al., 
2012). However this may be difficult to imitate as it appears to be changes to the 
shape of the protrusions on the capsid that gives AAV9 a different transduction 
profile than other AAV serotypes. As with all gene therapy methods the limiting 
factor is transfection efficiency, however a further rate limiting step for transfection 
using polymersomes is delivery of plasmid DNA to the nucleus. Polymersomes 
release their encapsulated DNA into the cytoplasm, from where it must get to the 
nucleus to initiate transfection. Transport of naked DNA through the cytoplasm to 
the nucleus is slow and inefficient (Lukacs et al., 2000).  
Once the DNA reaches the nucleus it must then pass the nuclear membrane to 
enter the nucleus. During this project it became apparent that dividing cells were 
more easily transfected than non-dividing cells, possibly because they are more 
transcriptionally active, or because the plasmid DNA can become trapped within the 
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nucleus during the reorganisation it undergoes during division (Dean et al., 2005).  
It may be possible to increase the transduction efficiency of these polymersomes by 
including a nuclear targeting motif on the plasmid DNA to improve the amount of 
DNA that is transported to the nucleus. 
Finally AAV5 was shown here to not be an appropriate choice of gene therapy 
vector for SMA due to the low transduction efficiency seen in motor neurons. 
However a point of interest here was the high level of transduction seen in the 
dorsal root and the possibility that AAV5 may be able to enter the spinal cord 
through retrograde transport. It would therefore be interesting to study the 
efficiency of motor neuron transduction following intramuscular injection of AAV5. 
However since SMA is a multi-system disorder it would be necessary to transduce 
more than just motor neurons in order to successfully provide therapy for SMA. 
Therefore AAV9 appears to be the most appropriate vector to provide gene therapy 
for SMA as it can achieve high levels of transduction in various tissues including 
the CNS.  
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